




(86) Date de dépôt PCT/PCT Filing Date: 2013/08/28
(87) Date publication PCT/PCT Publication Date: 2014/03/06
(85) Entrée phase nationale/National Entry: 2015/02/16
(86) N° demande PCT/PCT Application No.: EP 2013/067838
(87) N° publication PCT/PCT Publication No.: 2014/033181
(30) Priorité/Priority: 2012/08/28 (DK PA 2012 70508)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2006.01)
(71) Demandeur/Applicant:
AARHUS UNIVERSITET, DK
(72) Inventeurs/Inventors:
GULDBRANDTSEN, BERNT, DK;
SAHANA, GOUTAM, DK;
LUND, MOGENS SANDO, DK;
THOMSEN, BO, DK;
BENDIXEN, CHRISTIAN, DK;
PANITZ, FRANK BERND, DK
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : MARQUEURS GENETIQUES POUR LA RESISTANCE A LA MAMMITE
(54) Title: GENETIC MARKERS FOR MASTITIS RESISTANCE

Figure 1



(57) **Abrégé/Abstract:**

A method is provided for determining resistance to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom. Furthermore, methods are provided for determining a breeding value in respect of susceptibility to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom and assigning a breeding value based on said presence or absence



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

6 March 2014 (06.03.2014)



(10) International Publication Number

WO 2014/033181 A1

(51) International Patent Classification:

C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/EP2013/067838

(22) International Filing Date:

28 August 2013 (28.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2012 70508 28 August 2012 (28.08.2012) DK

(71) Applicant: AARHUS UNIVERSITET [DK/DK]; Nordre Ringgade 1, DK-8000 Aarhus C (DK).

(72) Inventors: GULDBRANDTSEN, Bernt; Sølystvej 3 O, DK-8830 Tjele (DK). SAHANA, Goutam; Blichers Allé 5, Foulum, DK-8830 Tjele (DK). LUND, Mogens Sandø; Vestergade 7, Ørum, DK-8830 Tjele (DK). THOMSEN, Bo; Ryhaven 49, DK-8210 Århus V (DK). BENDIXEN, Christian; Amstrupvej 7, DK-8860 Ulstrup (DK). PAN-ITZ, Frank Bernd; Øster Bordingvænget 19C, DK-8600 Silkeborg (DK).

(74) Agent: HØIBERG A/S; St. Kongensgade 59 A, DK-1264 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: GENETIC MARKERS FOR MASTITIS RESISTANCE

Figure 1



(57) Abstract: A method is provided for determining resistance to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom. Furthermore, methods are provided for determining a breeding value in respect of susceptibility to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom and assigning a breeding value based on said presence or absence

WO 2014/033181 A1

Genetic markers for mastitis resistance**Field of invention**

The present invention relates to a method for determining resistance to mastitis in a bovine subject comprising detecting at least one genetic marker associated with mastitis resistance. Furthermore, the present invention relates to a kit for detecting the presence or absence of at least one genetic marker associated with resistance to mastitis.

Background of invention

Mastitis is the inflammation of the mammary gland or udder of the cow resulting from infection or trauma and mastitis is believed to be the most economically important disease in cattle. The disease may be caused by a variety of agents. The primary cause of mastitis is the invasion of the mammary gland via the teat end by microorganisms. Mastitis may be clinical or sub-clinical, with sub-clinical infection preceding clinical manifestations. Clinical mastitis (CM) can be detected visually through observing red and swollen mammary glands i.e. red swollen udder, and through the production of clotted milk. Once detected, the milk from mastitic cows is kept separate from the vat so that it will not affect the overall milk quality. Sub-clinical mastitis is a type of mastitis characterized by high somatic cell counts (SCC), a normal or elevated body temperature, and milk samples that should test positive on culture. Thus, sub-clinical mastitis cannot be detected visually by swelling of the udder or by observation of the gland or the milk produced. Because of this, farmers do not have the option of diverting milk from sub-clinical mastitic cows. However, this milk is of poorer quality than that from non-infected cows and can thus contaminate the rest of the milk in the vat.

Mastitis can be detected by the use of somatic cell counts (SCC) in which a sample of milk from a cow is analysed for the presence of somatic cells (white blood cells). Somatic cells are part of the cow's natural defence mechanism and cell counts rise when the udder becomes infected. The number of somatic cells in a milk sample can be estimated indirectly by rolling-ball viscometer and Coulter counter.

As mastitis results in reduced quantity and quality of milk and products from milk, mastitis results in economic losses to the farmer and dairy industry. Therefore, the ability to determine the genetic basis of resistance to mastitis in a bovine is of immense economic significance to the dairy industry both in

terms of daily milk production but also in breeding management, selecting for bovine subjects with resistance to mastitis. A method of genetically selecting bovine subjects with improved resistance that will yield cows less prone to mastitis would be desirable.

Many studies have attempted to detect quantitative trait loci (QTL) affecting mastitis (e.g. Schrooten *et al.* 2000; Boichard *et al.* 2003), so that the QTL information could be utilized through marker assisted selection (MAS). Most studies, so far, have identified QTL for somatic cell score (SCS), an indicator trait for clinical mastitis (CM), and not directly for CM. Although these two traits have a high genetic correlation (Lund *et al.* 1999), it is not known if the QTL that have been identified for SCS also affect CM. It has been shown that persistently high somatic cell count (SCC) levels are mainly a sign of subclinical mastitis which is most often caused by contagious bacteria such as *Streptococcus aureus* and *Streptococcus agalactiae* (de Haas *et al.*, 2002). Incidences of acute clinical mastitis are more often caused by environmental bacteria such as *Escherichia coli* and in these infections the SCC levels increase rapidly but are soon dropping to normal level when the infection is cured. Therefore an acute infection may not be detected by high SCC levels. Another limitation of earlier studies is that the QTL were detected by linkage analysis (LA) with low precision for QTL position and, furthermore, LA associations between markers and the trait can only be used for selection within families. On the contrary, a combined linkage disequilibrium and linkage analysis (LDLA) can potentially fine-map a QTL to a chromosomal region less than 1 cM using closely linked markers (Meuwissen & Goddard 2000). The markers within the LDLA confidence interval can be used to identify haplotypes with predictive ability in the general population. These haplotypes are easier to use in MAS than the LA markers.

Once mapped, a genetic marker can be usefully applied in marker assisted selection. In the present invention genetic markers associated to clinical mastitis and/or SCS have been identified in the bovine genome, which allows for a method for determining whether a bovine subject and its off-spring will be resistant to mastitis.

Summary of invention

It is of significant economic interest within the cattle industry to be able to select bovine subjects with increased resistance to mastitis and thereby avoid economic losses in connection with animals suffering from mastitis. The genetic predisposition for resistance to mastitis may be detected by the present

invention. The present invention offers a method for determining the resistance to mastitis in a bovine subject based on genetic markers which are associated with and/or linked to resistance to mastitis.

One aspect of the present invention relates to method for determining resistance to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom, wherein said at least one genetic marker is located in a region of the bovine genome selected from the group consisting of regions 1-61 identified in table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6.

In another aspect, the present invention relates to a method for selecting a bovine subject for breeding purposes, said method comprising determining resistance to mastitis of said bovine subject and/or off-spring therefrom by a method of the invention, and then selecting or not selecting said bovine subject for breeding based on said determined breeding value.

A third aspect of the present invention relates to a kit for use in detecting the presence or absence in a bovine subject of at least one genetic marker associated with resistance to mastitis, comprising at least one detection member for determining a genetic marker located in a region of the bovine genome selected from the group consisting of regions 1-61 identified in table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6.

In a fourth aspect, the invention relates to the use of the kit mentioned above for detecting the presence or absence in a bovine subject of at least one genetic marker associated with resistance to mastitis.

In a fifth aspect, the present invention relates to a method for estimating a breeding value in respect of susceptibility to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom, wherein said at least one genetic marker is located in a region of the bovine genome selected from the group consisting of re-

gions 1-61 of table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6.

Description of Drawings

Figure 1. Genome-wide scan for mastitis trait CM (Clinical mastitis all lactations): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 2. Genome-wide scan for mastitis trait SCS (Somatic cell score): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 3. Genome-wide scan for mastitis trait CM11 (Clinical mastitis first lactation, -15 to 50 days): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 4. Genome-wide scan for mastitis trait CM12 (Clinical mastitis first lactation, 51 to 305 days): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 5. Genome-wide scan for mastitis trait CM2 (Clinical mastitis second lactation, -15 to 305 days): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 6. Genome-wide scan for mastitis trait CM3 (Clinical mastitis third lactation, -15 to 305 days): $-\log_{10}$ of the p-value analysis for association with SNPs. Chromosomes are shown in alternating colors for clarity. The dotted line represents suggestive association [$-\log_{10}(\text{p-value}) = 4$] as considered in the present example.

Figure 7. Manhattan plot for the clinical mastitis between -15 and 50 days after 1st calving (CM11). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 8. Manhattan plot for clinical mastitis between -51 and 305 days after 1st calving (CM12). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 9. Manhattan plot for clinical mastitis between -15 and 305 days after 2nd calving (CM2). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 10. Manhattan plot for clinical mastitis between -15 and 305 days after 3rd calving (CM3). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 11. Manhattan plot for clinical mastitis index (CM5). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 12. Manhattan plot for log average somatic cell count in 1st lactation (SCC1). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 13. Manhattan plot for log average somatic cell count in 2nd lactation (SCC2). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 14. Manhattan plot for log average somatic cell count in 3rd lactation (SCC3). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 15. Manhattan plot for log average somatic cell count index (SCC). The X-axis shows the chromosomes and SNPs. The Y-axis shows the $-\log_{10}$ (p-value) for each SNP which reflects the strength of association for a SNP with the trait analyzed.

Figure 16: The association of SNP variants identified from whole genome sequence with the first lactation clinical mastitis (CM11) at 88-96 Mb on bovine chromosome 6. The x-axis is the SNP number as order in the bovine genome assembly (UMD3.1) and the y-axis is $-\log_{10}$ (p-values).

Figure 17. Table 6

Figure 18. Manhattan plot for BTA5, A. Chr-5.1 MAS11; B. Chr-5.2 MAS12; C. Chr-5.3 MAS2; D. Chr-5.4 MAS3; D. Chr-5.5 MAS-INDEX; F. Chr-5.6 SCS1; G. Chr-5.7 SCS2; H. Chr-5.8 SCS3; I. Chr-5.9 SCS-INDEX

Figure 19. Manhattan plot for BTA6, A. Chr-6.1 MAS11; B. Chr-6.2 MAS12; C. Chr-6.3 MAS2; D. Chr-6.4 MAS3; D. Chr-6.5 MAS-INDEX; F. Chr-6.6 SCS1; G. Chr-6.7 SCS2; H. Chr-6.8 SCS3; I. Chr-6.9 SCS-INDEX

Figure 20. Manhattan plot for BTA13, A. Chr-13.1 MAS11; B. Chr-13.2 MAS12; C. Chr-13.3 MAS2; D. Chr-13.4 MAS3; D. Chr-13.5 MAS-INDEX; F. Chr-13.6 SCS1; G. Chr-13.7 SCS2; H. Chr-13.8 SCS3; I. Chr-13.9 SCS-INDEX

Figure 21. Manhattan plot for BTA16, A. Chr-16.1 MAS11; B. Chr-16.2 MAS12; C. Chr-16.3 MAS2; D. Chr-16.4 MAS3; D. Chr-16.5 MAS-INDEX; F. Chr-16.6 SCS1; G. Chr-16.7 SCS2; H. Chr-16.8 SCS3; I. Chr-16.9 SCS-INDEX

Figure 22. Manhattan plot for BTA19, A. Chr-19.1 MAS11; B. Chr-19.2 MAS12; C. Chr-19.3 MAS2; D. Chr-19.4 MAS3; D. Chr-19.5 MAS-INDEX; F. Chr-19.6 SCS1; G. Chr-19.7 SCS2; H. Chr-19.8 SCS3; I. Chr-19.9 SCS-INDEX

Figure 23. Manhattan plot for BTA20, A. Chr-20.1 MAS11; B. Chr-20.2 MAS12; C. Chr-20.3 MAS2; D. Chr-20.4 MAS3; E. Chr-20.5 MAS-INDEX; F. Chr-20.6 SCS1; G. Chr-20.7 SCS2; H. Chr-20.8 SCS3; I. Chr-20.9 SCS-INDEX

Figure 24. SNP polymorphisms on BTA20 associated with mastitis. The round circles are from the single marker analysis with linear mixed model using the full sequence variants; the black line is the haplotype analysis with 50K genotypes; the green line is the haplotype analysis with 50K including the SNP (rs133218364) located at 33,642,072 Bp on BTA20 as fixed effect in the model; the red line is the haplotype analysis with 50K including the SNP (rs133596506) located at 35,969,994 Bp on BTA20 as fixed effect in the model.

Detailed description of the invention

The present invention relates to genetic determinants of mastitis resistance in dairy cattle. The occurrence of mastitis, both clinical and sub-clinical mastitis involves substantial economic loss for the dairy industry. Therefore, it is of economic interest to identify those bovine subjects that have a genetic predisposition for mastitis resistance. Bovine subjects with such genetic predisposition are carriers of desired traits, which can be passed on to their offspring.

Terms and definitions

The term “genetic marker” refers to a variable nucleotide sequence (polymorphism) of the DNA on the bovine chromosome and distinguishes one allele from another. The variable nucleotide sequence can be identified by methods known to a person skilled in the art for example by using specific oligonucleotides in for example amplification methods and/or observation of a size difference. However, the variable nucleotide sequence may also be detected by sequencing or for example restriction fragment length polymorphism analysis, or by different hybridization techniques, such as southern blotting or array technologies using oligonucleotide probes. The variable nucleotide sequence may be represented by a deletion, an insertion, repeats, and/or a point mutation.

One type of genetic marker is a microsatellite marker, which may be located in/or coupled to a quantitative trait locus. Microsatellite markers refer to short sequences repeated after each other. In short sequences are for example one nucleotide, such as two nucleotides, for example three nucleotides, such as four nucleotides, for example five nucleotides, such as six nucleotides, for example seven

nucleotides, such as eight nucleotides, for example nine nucleotides, such as ten nucleotides. However, changes sometimes occur and the number of repeats may increase or decrease. The specific definition and locus of the polymorphic microsatellite markers can be found in the USDA genetic map (Kappes et al. 1997; or by following the link to U.S. Meat Animal Research Center <http://www.marc.usda.gov/genome/cattle/cattle.html>). Another type of genetic marker is a single nucleotide polymorphism (SNP). In cattle, it is possible to simultaneously genotype large numbers of SNP markers using the commercially available kits, for example the bovine SNP genotyping kits provided by Illumina Inc.

It is appreciated that the genetic markers of the present invention are genetically linked to traits for mastitis resistance in a bovine subject. However, it is also understood that a number of additional genetic markers may be found in neighbouring DNA regions, and that these markers can be used to infer the identity of genetic markers associated with mastitis provided herein, when such additional genetic markers are genetically coupled to the markers provided by the present invention. Such additional genetic markers are obvious equivalents of the markers provided herein, and such markers are also within the scope of the present invention.

The term 'Quantitative trait locus (QTL)' is a region of DNA that is associated with a particular trait (e.g., mastitis resistance, somatic cell count, or clinical mastitis). Though not necessarily genes themselves, QTLs are regions of DNA that are closely linked to the genes that underlie the trait in question.

The term "associated with" as used herein in regards to the genetic marker allele and/or combination of genetic marker alleles and phenotypic traits, is meant to comprise both direct and indirect genetic linkages. Thus, a genetic marker allele and/or combination of genetic marker alleles which are associated with a trait according to the present invention may be coupled to said trait by direct or indirect genetic linkages. Moreover, the term "trait associated with" as used herein in regards to a specific phenotype, relates to any phenotypic traits, which to any extent contribute to said phenotype. For example, the traits somatic cell count (SCC), somatic cell score (SCS), udder conformation (which comprises several quantitative measures, such as fore udder attachment, udder depth, udder texture etc.), and diagnostic variables (such as treated cases of clinical mastitis within a specific timeframe) contribute to the overall mastitis phenotype. Thus, the "traits associated with mastitis resistance", or "mastitis

resistance phenotypic traits” comprise SCC, SCS, CM11, CM12, CM2, CM3, CM, SCC3, SCC2, SCC1, SCC and diagnostic variables, including the subindexes of any of said phenotypic traits.

The term “genetically coupled” is used herein about two genomic loci, which tend to segregate together. Thus, an SNP marker allele, which is genetically coupled to another genetic marker allele associated with a specific phenotypic trait according to the present invention, is indicative of said genetic marker, and may consequently be detected in a sample as an alternative of detecting said genetic marker associated with said phenotypic traits, for example traits associated with mastitis resistance.

It is furthermore appreciated that the nucleotide sequences of the genetic marker allele or combination of marker alleles of the present invention are genetically associated with phenotypic traits of the present invention in a bovine subject. Consequently, it is also understood that a number of genetic markers may be comprised in the nucleotide sequence of the DNA region(s) flanked by and including the genetic markers according to the method of the present invention.

The term “gene” is as used herein is meant to comprise coding regions as well as non-coding region of any genes, as well as upstream and downstream regions of the open reading frame. Thus, a genetic marker “located in a gene” may be located in exons, introns, or upstream or downstream of the open reading frame, for example in the area of 1000 nucleotides or more upstream or downstream of the open reading frame of the gene in question.

Specifically, the transcribed region of a gene is considered to be comprised in the term “gene”, and markers located in a gene, thus, includes any marker located in a transcribed region of that gene.

Linkage disequilibrium

Linkage disequilibrium (LD) reflects recombination events dating back in history and the use of LD mapping within families increases the resolution of mapping. LD exists when observed haplotypes in a population do not agree with the haplotype frequencies predicted by multiplying together the frequency of individual genetic markers in each haplotype. In this respect the term haplotype means a set of closely linked genetic markers present on one chromosome which tend to be inherited together. In order for LD mapping to be efficient the density of genetic markers needs to be compatible with the distance across which LD extends in the given population. Linkage disequilibrium reflects the extent to

which different genetic markers tend to be co-inherited in a population. In cattle the level of LD is high compared to for example human, due to i.a. inbreeding and historical bottlenecks. Therefore, the identity of one genetic marker can often be inferred from the identity of alternative genetic markers, which are in LD.

Granddaughter design

The granddaughter design includes analysing data from DNA-based markers for grand sires that have been used extensively in breeding and for sons of grand sires where the sons have produced offspring. The phenotypic data that are to be used together with the DNA-marker data are derived from the daughters of the sons. Such phenotypic data could be for example milk production features, features relating to calving, meat quality, or disease. One group of daughters have inherited one allele from their father whereas a second group of daughters have inherited the other allele from their father. By comparing data from the two groups information can be gained whether a fragment of a particular chromosome is harbouring one or more genes that affect the trait in question. It may be concluded whether a QTL is present within this fragment of the chromosome. A prerequisite for performing a granddaughter design is the availability of detailed phenotypic data. In the present invention such data have been available (<http://www.lr.dk/kvaeg/diverse/principles.pdf>). Genes conferring quantitative traits to an individual may be found in an indirect manner by observing pieces of chromosomes that act as if one or more gene(s) is located within that piece of the chromosome. In contrast, DNA markers can be used directly to provide information of the traits passed on from parents to one or more of their offspring when a number of DNA markers on a chromosome have been determined for one or both parents and their offspring. The markers may be used to calculate the genetic history of the chromosome linked to the DNA markers.

Bovine subject

The term "bovine subject" refers to cattle of any breed and is meant to include both cows and bulls, whether adult or newborn animals. No particular age of the animals are denoted by this term. One example of a bovine subject is a member of the Holstein breed. In one preferred embodiment, the bovine subject is a member of the Holstein-Friesian cattle population. In one embodiment, the bovine subject is a member of the Danish and/or Swedish Holstein cattle population. In another embodiment, the bovine subject is a member of the Holstein Swartbont cattle population. In another embodiment, the bovine subject is a member of the Deutsche Holstein Schwarzbunt cattle population. In another

embodiment, the bovine subject is a member of the US Holstein cattle population. In one embodiment, the bovine subject is a member of the Red and White Holstein breed. In another embodiment, the bovine subject is a member of the Deutsche Holstein Schwarzbunt cattle population.

In one embodiment, the bovine subject is a member of any family, which include members of the Holstein breed. In one preferred embodiment the bovine subject is a member of the Danish Red population. In another preferred embodiment the bovine subject is a member of the Finnish Ayrshire population. In yet another embodiment the bovine subject is a member of the Swedish Red and White population. In a further embodiment the bovine subject is a member of the Danish Holstein population. In another embodiment, the bovine subject is a member of the Swedish Red and White population. In yet another embodiment, the bovine subject is a member of the Nordic Red population. In yet another embodiment, the bovine subject is a member Nordic Holstein, Danish Jersey and Nordic Red breed

In one embodiment of the present invention, the bovine subject is selected from the group consisting of Swedish Red and White, Danish Red, Finnish Ayrshire, Holstein-Friesian, Danish Holstein and Nordic Red. In another embodiment of the present invention, the bovine subject is selected from the group consisting of Finnish Ayrshire and Swedish Red and White cattle. In another embodiment of the present invention, the bovine subject is selected from the group consisting of Finnish Ayrshire and Swedish Red and White cattle.

Mastitis resistance

The term “mastitis” relates to the inflammation of the mammary gland of the udder of a cow. In the present application the term “mastitis” is used to describe both clinical mastitis and sub-clinical mastitis, which can be characterized for example by high somatic cell score (SCS).

The terms “mastitis resistance” and ‘resistance to mastitis’ are used interchangeable and relates to the fact that some bovine subjects are not as prone to mastitis as are other bovine subjects, in other words, some bovine subjects are less susceptible to mastitis than other bovine subjects. Thus, the term “resistance” as used herein, refers to any level of reduction in mastitis, ranging from a minute reduction of 0.5 % or less to complete absence of mastitis, i.e. complete resistance. When performing analyses of a number of bovine subjects as in the present invention in order to determine genetic markers that are associated with resistance to mastitis, the traits implying resistance to mastitis may

be observed by the presence or absence of genetic markers linked to occurrence of clinical mastitis and/or sub-clinical mastitis in the bovine subjects analyzed. It is understood that mastitis resistance comprise resistance to traits, which affect udder health in the bovine subject or its off-spring. Thus, mastitis resistance of a bull is physically manifested by its female off-spring.

Mastitis resistance is inversely correlated with susceptibility to mastitis, i.e. a bovine subject with high mastitis resistance has low susceptibility to mastitis. Thus, the term “susceptible to mastitis” as used herein is meant to indicate that a bovine subject has a relatively higher likelihood of suffering from mastitis, or having a trait indicative of mastitis.

Traits indicative of mastitis resistance

Daughters of bulls can be scored for mastitis resistance on the basis of a number of different quantitative and qualitative parameters. Specifically, mastitis resistance may be observed according to the present invention on the basis of specific traits, which are indicative of mastitis resistance. One such trait indicative of mastitis resistance in a population of cattle is recorded cases of clinical mastitis. Other examples of traits are somatic cell count (SCC), or somatic cell score (SCS), which is defined as the mean of $\log^{10}$ transformed somatic cell count values (in 10,000/mL) obtained from the milk recording scheme. The mean is for example taken over the period 10 to 180 days after calving. Estimated breeding values (EBV) for traits of sons may be calculated using a single trait Best Linear Unbiased Prediction (BLUP) animal model ignoring family structure. Examples of specific quantitative traits indicative of mastitis resistance are provided in the table below:

Table 1. Definitions of exemplary traits associated with mastitis according to the present invention.

Trait No.	Trait abbreviation	Trait definitions
1	CM11	Clinical mastitis (1) or not (0) between -15 and 50 days after 1st calving
2	CM12	Clinical mastitis (1) or not (0) between 51 and 305 days after 1st calving
3	CM2	Clinical mastitis (1) or not (0) between -15 and 305 days after 2nd calving

4	CM3	Clinical mastitis (1) or not (0) between -15 and 305 days after 3rd calving
5	CM	Clinical mastitis: $0.25*CM11 + 0.25*CM12 + 0.3*CM2 + 0.2*CM3$
6	SCC1	Log. somatic cell count average in 1st lactation
7	SCC2	Log. somatic cell count average in 2nd lactation
8	SCC3	Log. somatic cell count average in 3rd lactation
9	SCC	Log somatic cell count: $0.5*SCC1 + 0.3*SCC2 + 0.2*SCC3$

In one embodiment of the present invention, the methods and kits described herein relates to mastitis resistance, such as resistance to clinical mastitis and/or resistance to sub-clinical mastitis, such as detected by somatic cell counts or SCS. More specifically, the methods and kits of the invention relates in one embodiment to genetic markers associated with at least one trait indicative of mastitis, such trait in a preferred embodiment being selected from CM11 (Clinical mastitis (1) or not (0) between -15 and 50 days after 1st calving), CM12 (Clinical mastitis (1) or not (0) between 51 and 305 days after 1st calving), CM2 (Clinical mastitis (1) or not (0) between -15 and 305 days after 2nd calving), CM3 (Clinical mastitis (1) or not (0) between -15 and 305 days after 3rd calving), CM (Clinical mastitis: $0.25*CM11 + 0.25*CM12 + 0.3*CM2 + 0.2*CM3$), SCC1 (Log. somatic cell count average in 1st lactation), SCC2 (Log. somatic cell count average in 2nd lactation), SCC3 (Log. somatic cell count average in 3rd lactation) and SCC (Log somatic cell count: $0.5*SCC1 + 0.3*SCC2 + 0.2*SCC3$). In a preferred embodiment, the trait is clinical mastitis, for example any trait selected from CM11, CM12, CM2, CM3 or CM. As specified in table 1, CM is an index for clinical mastitis based on CM11, CM12, CM2 and CM3.

In yet another embodiment, the method and kit of the present invention primarily relates to resistance to clinical mastitis in combination with resistance to sub-clinical mastitis such as detected by somatic cell counts or SCS, for example SCC1, SCC2, SCC3 or SCC. The methods and kits of the present invention comprise detecting the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of a bovine subject or off-spring therefrom,

wherein said at least one trait is selected from somatic cell count (SCC), somatic cell score (SCS) and/or clinical mastitis.

In general, increased levels of SCS are indicative of mastitis, e.g. subclinical mastitis. The level of SCC may be increased compared to previous measures for the same bovine subject, or compared to an average SCC for the given population, breed, or family. The SCS level may be measured at any time, and may be separate measures or a mean value over one lactation period. For example, an SCC level above 100.000 cells/ml milk, such as above 200.000, for example above 300.000 cells/ml milk, such as above 400.000, for example above 500.000 cells/ml milk, such as above 600.000, cell/ml milk is indicative of mastitis, such as clinical or subclinical mastitis. Therefore, SCC levels of such magnitudes are considered as traits indicative of reduced susceptibility to mastitis according to the present invention. However, the level of SCC indicative of mastitis resistance or susceptibility to mastitis may vary for different bovine subjects, breeds and families.

The present invention can be used to estimate breeding values in respect of mastitis resistance or susceptibility to mastitis. True breeding value is the genetic merit of an individual which can be conceptually defined as twice the average deviation of its offspring from the population mean when mated randomly to an infinite population. It is an estimate of the ability of an individual to produce superior offspring. True breeding values are not known but can be estimated from the animals own performance and/or the performance of its offspring and/or other relatives. In addition to, or instead of, phenotypic performance, information about animals genotypes at certain genes or markers associated with the trait of interest can be used in breeding value estimation procedures. Use of such information can increase the reliability of the breeding values and make, for example, selection possible at a younger age. In one embodiment, the at least on genetic marker indicative of mastitis resistance is used to estimate the breeding value of a bovine subject.

The trait indicative of mastitis resistance may be recalculated into a breeding value for every bovine subject, for example every sire. Thus, the genetic markers of the methods and kits of the present invention may be used for selection of bovine subjects with increased breeding values, and detection of at least on genetic marker indicative of mastitis resistance according to the present invention is indicative of an increased breeding value of the bovine subject. For example the breeding value is increased by at least 0.5%, such as at least 1%, such as at least 2, 3, 4,5 ,6 ,7, 8, 9, for example at least 10%.

Sample

The method according to the present invention includes analyzing a sample of a bovine subject, wherein said sample may be any suitable sample capable of providing the bovine genetic material for use in the method. The type of sample is not important, as long as the sample comprise genetic material specific for the bovine subject, which is analysed. Thus, any sample comprising genetic material from the bovine subject can be used. Preferably, the sample is a sample, which is easily obtained from the bovine subject, preferably a sample, which can be obtained without any invasive procedures.

Thus, mastitis resistance is determined by detecting the absence or presence of a genetic marker allele in a sample of any source comprising genetic material. The bovine genetic material may for example be extracted, isolated and/or purified if necessary. The samples may be fresh or frozen. Detection of a genetic marker may be performed on samples selected from the group consisting of blood, semen (sperm), urine, liver tissue, muscle, skin, hair, follicles, ear, tail, fat, testicular tissue, lung tissue, saliva, spinal cord biopsy and/or any other tissue.

In preferred embodiments the sample is selected from the group consisting of semen (sperm), blood, urine, skin, hair, ear, tail, and muscle. In another preferred embodiment the sample is selected from the group consisting of blood. In particularly preferred embodiments the sample is milk. In another particularly preferred embodiment the sample is skin tissue. In yet another particularly preferred embodiment the sample is muscle. In a most preferred embodiment the sample is semen (sperm).

For microsatellite or SNP genotyping, nucleic acid may be extracted from the samples by a variety of techniques. For example Genomic DNA may be isolated from the sample by treatment with proteinase K followed by extraction with phenol (see e.g. Sambrook et al. 1989). However, the sample may also be used directly.

The amount of the nucleic acid used for microsatellite or SNP genotyping for detection of a genetic marker according to the method of the present invention is in the range of nanograms to micrograms. It is appreciated by the person skilled in the art that in practical terms no upper limit for the amount of nucleic acid to be analysed exists. The problem that the skilled person encounters is that the amount of sample to be analysed is limited. Therefore, it is beneficial that the method of the present invention

can be performed on a small amount of sample and thus a limited amount of nucleic acid in the sample is required. The amount of the nucleic acid to be analysed is thus at least 1 ng, such as at least 10 ng, for example at least 25 ng, such as at least 50 ng, for example at least 75 ng, such as at least 100 ng, for example at least 125 ng, such as at least 150 ng, for example at least 200 ng, such as at least 225 ng, for example at least 250 ng, such as at least 275 ng, for example at least 300 ng, 400 ng, for example at least 500 ng, such as at least 600 ng, for example at least 700 ng, such as at least 800, ng, for example at least 900 ng or such as at least 1000 ng.

In one preferred embodiment the amount of nucleic acid as the starting material for the method of the present invention is 20-50 ng. In a specifically preferred embodiment, the starting material for the method of the present invention is at 30-40 ng.

Chromosomal regions and markers

BTA is short for *Bos taurus* autosome.

One aspect of the present invention relates to a method for determining resistance to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom, wherein said at least one genetic marker is located in a genetic region of the bovine genome selected from region 1-61, as specified in table 2.

Table 2

1	2	3	4	5	6	9	10
Regi- on No.	Chr	Start- SNP	Start Pos.	End- SNP	End Pos.	Most sig. SNP name	Top SNP Pos
1	1	19479	76096755	19481	76099500	Bo- vineHD0100021877	76096755
2	1	24128	96507612	24500	97612639	Bo- vineHD0100027421	96507612
3	1	33740	13523619 0	35634	14179171 7	Bo- vineHD0100038448	13528594 9
4	3	16606	62218619	16846	63185254	ARS-BFGL-NGS-	62615411

						57708	
5	3	23488	92199528	25665	10136492 0	Bo- vineHD0300028997	10132386 6
6	4	5485	20993524	7036	27829152	Bo- vineHD0400008053	27829152
7	4	8924	36558317	10527	44073697	Hapmap24419-BTA- 162106	36558317
8	4	13365	55763368	15735	65519029	Bo- vineHD0400016706	61125903
9	4	23730	97674762	24213	99540028	Bo- vineHD0400027868	99540028
10	5	16168	67417898	17489	72243381	ARS-BFGL-NGS- 70198	72243381
11	5	20435	84539347	27159	10994823 2	Bo- vineHD0500024659	86998734
12	6	4475	18036724	7462	29334848	Bo- vineHD0600006497	23549700
13	6	13573	51683927	13598	51755112	Bo- vineHD0600014264	51731374
14	6	18708	71082832	26792	10275784 1	Bo- vineHD0600024355	88919352
15	7	1236	5202111	1708	6663939	Bo- vineHD0700001692	5927298
16	7	2907	14485587	4789	22681472	Bo- vineHD0700005054	18032163
17	7	7174	31432538	10157	41607314	Bo- vineHD4100005904	33485418
18	7	10795	44074131	15561	63839308	Bo- vineHD0700018462	63839308
19	7	26534	10475330 0	27857	10958467 7	Bo- vineHD0700031919	10940639 3

20	8	801	3101470	1541	5993074	Bo- vineHD0800001554	4844864
21	8	4831	20417406	8352	35930652	Bo- vineHD0800006734	22287380
22	9	1495	7453669	1591	7749361	Bo- vineHD0900001741	7735822
23	9	2848	12242079	3079	13035215	Bo- vineHD0900003387	12963863
24	9	21143	86380558	21144	86381215	Bo- vineHD0900024208	86380558
25	10	12689	47838479	13661	51407940	Bo- vineHD1000014875	49359005
26	10	15921	62168320	20229	79735238	Bo- vineHD1000021167	74285470
27	10	22654	89224445	24333	94083525	BTA-80363-no-rs	90484606
28	11	68	210963	1555	4567617	Bo- vineHD4100008447	210963
29	11	23860	88133102	24010	88778399	Bo- vineHD1100025584	88778399
30	12	787	2569573	933	2991581	Bo- vineHD1200000926	2917822
31	12	3217	11578657	7626	27097379	Bo- vineHD1200006858	22865273
32	12	11277	44331491	11285	44349649	Bo- vineHD1200012284	44331491
33	12	15918	62561736	17398	68494212	Bo- vineHD1200017277	63068164
34	13	11798	53471793	15089	70173150	Bo- vineHD1300017074	59588546
35	14	3505	13282075	5041	20691077	Bo- vineHD1400005926	20662703

36	14	9864	43961811	15451	69623868	Bo- vineHD1400014643	51548605
37	15	2329	9897946	2334	9915788	Bo- vineHD1500002610	9897946
38	15	6316	26178933	8176	33293128	Bo- vineHD1500008366	31105101
39	15	9855	39284002	13327	52111223	Bo- vineHD1500012201	43914509
40	15	17079	66540919	17084	66551171	Bo- vineHD1500019116	66543720
41	16	1694	8171169	2172	10545502	Bo- vineHD1600002326	8171169
42	16	3534	15737429	3596	16009799	Bo- vineHD1600004272	15784091
43	16	5299	21799660	16175	64955150	Bo- vineHD1600014622	52924145
44	17	512	2467836	3752	13800376	Bo- vineHD1700002674	9472006
45	17	16389	61406860	16431	61535420	ARS-BFGL-NGS- 26121	61522805
46	18	6383	21603442	6944	23535823	Bo- vineHD1800006666	21606994
47	18	11892	41653211	13902	48570545	Bo- vineHD1800013234	44778431
48	19	2020	8230088	3676	14585690	Bo- vineHD1900003860	14578566
49	19	7734	27998517	8035	29383514	Bo- vineHD1900008608	29320178
50	19	9209	33351947	12120	46467474	Bo- vineHD1900012270	43098630
51	19	12750	49013784	16762	62339802	Bo-	55615219

						vineHD1900015719	
52	20	5111	18072225	5122	18110885	Bo- vineHD2000005443	18110885
53	20	7852	28291423	14407	55744850	Bo- vineHD2000010279	35981673
54	20	14681	56557595	19739	71359405	Bo- vineHD2000019538	67376802
55	21	11020	43772475	11021	43773986	Bo- vineHD2100012534	43772475
56	22	6727	24494154	8368	31397754	Hapmap38325-BTA- 53915	25113789
57	23	1077	4758944	3549	14524909	Bo- vineHD2300002833	11512182
58	23	4429	18006108	7776	28819118	Bo- vineHD2300007202	26369699
59	23	9221	33362170	9673	35604326	Bo- vineHD2300010058	34251317
60	23	11058	41491498	13747	51051152	Bo- vineHD2300012843	44312928
61	25	3879	12927936	3879	12927936	Bo- vineHD2500003616	12927936

In one embodiment, the genetic marker of the invention is selected from the group of markers set forth in table 2, column 9 or 10.

In another embodiment, the genetic marker is selected from the group consisting of the SNPs set forth in tables 10, 12, 13, 15, 16, 18, 19, 21, 23 and 24, cf. the examples herein below.

In another embodiment, the genetic marker is located in a gene selected from the group consisting of the genes set forth in tables 11, 14, 17, 20, 22 and 25, cf. the examples herein below.

In another embodiment, the genetic markers is selected from the group consisting of ss86284888, rs41649041, ss61565956, ss86341106, ss86317725, ss86328358, rs41812941, ss86327354, and rs41940571 (cf. table 3).

In another embodiment, the genetic markers is selected from the group consisting of ss86328743, rs41618669, ss86284888, rs41580905, rs41649041, rs43706944, rs42189699, rs42553026, rs41664497, rs41664497, ss86290235, ss86340493, ss86305923, ss86330005, ss86340725, rs29015635, rs42895750, ss117968104, rs29017739, rs29001782, rs41588957, ss86307579, ss86317213, rs41610991, ss117968170, ss117968764, ss117968030, ss117968525, rs29019575, ss117968738, ss86326721, ss86341106, ss86341106, rs29010419, rs29022799, ss86278591, ss86337596, rs43338539, ss86296213, rs42766480, rs41617692, ss117963883, rs43475842, rs29019286, ss86292503, ss86317725, ss86290731, ss86332750, ss86335834, ss86340346, ss105239139, ss117971362, ss86287919, ss86329615, ss86301882, ss86328358, ss117971370, ss117971325, ss86339873, ss117971671, ss117971176, rs41807595, rs41807595, rs29023167, ss86303613, ss86283374, ss86328473, ss86307986, rs41603818, rs41812941, ss105262977, ss105262977, rs42465037, ss86327354, ss86327432, ss61484557, rs42329877, ss86333005, ss86306906, ss117972835, rs41938511, rs42542144, rs41940571, rs41947330, rs29018751, rs41581087, ss105263178, rs41641052, rs41641055, ss86292111, rs41600165 and ss86306865 (cf. table 4).

Due to linkage disequilibrium as described herein, the present invention also relates to methods for determining the resistance to mastitis in a bovine subject, wherein the at least one genetic marker is linked or genetically coupled to genetic determinants of a bovine trait for resistance to mastitis.

In order to determine resistance to mastitis in a bovine subject, it is appreciated that more than one genetic marker may be employed in the present invention. For example the at least one genetic marker may be a combination of at least two or more genetic markers such that the accuracy may be increased, such as at least three genetic markers, for example four genetic markers, such as at least five genetic markers, for example six genetic markers, such as at least seven genetic markers, for example eight genetic markers, such as at least nine genetic markers, for example ten genetic markers.

The at least one genetic marker may be located on at least one bovine chromosome, such as two chromosomes, for example three chromosomes, such as four chromosomes, for example five chromosomes, and/or such as six chromosomes. Thus, the at least one genetic marker may be a combination of markers located on different chromosomes. The at least one genetic marker is selected from any of the individual markers of the tables shown herein below.

In one embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA1 in a region delineated by BovineHD Genotyping BeadChip SNP#19479 and SNP#19481 and/or in a region between base nos. 76096755 and 76099500, for example, the marker is BovineHD0100021877 or is BovineHD Genotyping BeadChip SNP#76096755, or is linked to any of said markers

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA3 in a region delineated by BovineHD Genotyping BeadChip SNP#23488 and SNP#25665 and/or in a region between base nos. 92199528 and 101364920, for example, the marker is BovineHD0300028997 or is BovineHD Genotyping BeadChip SNP#101323866, or is linked to any of said markers.

BTA5

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA5 in a region delineated by BovineHD Genotyping BeadChip SNP#20435 and SNP#27159 and/or in a region between base nos. 84539347 and 109948232, for example, the marker is BovineHD0500024659 or is BovineHD Genotyping BeadChip SNP#86998734, or is linked to any of said markers.

In one embodiment, the genetic marker is located on the bovine chromosome BTA5 in a region between 84-95 Mb, for example the marker is Chr5_92753829 and/or the trait is mastitis resistance, such as CM11. In one embodiment, the genetic marker is selected from the group consisting of Chr5_92753829, BovineHD0500024659, Chr5_87360522, BovineHD0500026657, Chr5_92753829, Chr5_87360522, Chr5_94040670, Chr5_89528205 and Chr5_87360522 (cf. table 10), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as indicated in table 10.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000022360, ENSBTAG00000005833, ENSBTAG00000001673, ENSBTAG00000013202, ENSBTAG00000047048, ENSBTAG00000046178, ENSBTAG00000020715, ENSBTAG00000030493, ENSBTAG00000013541, ENSBTAG00000008541 and ENSBTAG00000009444, cf. table 11.

BTA6

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA6 in a region delineated by BovineHD Genotyping BeadChip SNP#18708 and SNP#26792 and/or in a region between base nos. 71082832 and 102757841, for example, the marker is BovineHD0600024355 or is BovineHD Genotyping BeadChip SNP#88919352, or is linked to any of said markers.

However, in a particularly preferred embodiment, the at least one genetic marker is located on the bovine chromosome BTA6 in a region between base nos. 88000560 and 95999980. In a specifically preferred embodiment, the at least one genetic marker is BovineHD0600024355 located at 88,919,352 Bp on BTA6. In one embodiment, BovineHD0600024355 is a genetic marker associated with clinical mastitis, such as CM11.

For example, the at least one genetic marker is located in the region between base nos. 89,052,210 and 89,059,348 on BTA6. Thus, in one preferred embodiment, the genetic marker associated with at least one trait indicative of mastitis, such as clinical mastitis, for example CM11, is located in the neuropeptide FF receptor 2 (NPFFR2) gene, in particular in the coding region of NPFFR2. In one embodiment, the genetic marker associated with mastitis is the chr6_89059253 SNP, which is located at 89,059,253 Bp on BTA6. This SNP is a G-A substitution. However, as alternative SNPs located within the NPFFR2 gene are strongly coupled to the chr6_89059253 SNP, any genetic marker polymorphism located in the NPFFR2 gene is associated with a trait indicative of mastitis. Thus, the present invention relates to methods of determining mastitis and/or a breeding value as well as methods for selected cattle for breeding, and kits, wherein the at least one genetic marker is located in the NPFFR2 gene or is genetically coupled to the NPFFR2 gene, and in one preferred embodiment, the at least one genetic marker is the chr6_89059253 SNP and/or any genetic marker polymorphism genetically coupled thereto. Thus, in one embodiment, the genetic marker is the G/A SNP located at 89,059,253

Bp (UMD3.1), wherein the A allele is associated with mastitis and the G allele is associated with resistance to mastitis.

In one embodiment, the genetic marker is located on the bovine chromosome BTA6 in a region between 88-96 Mb, for example the marker is Chr6_88977023 and/or the trait is mastitis resistance, such as CM11. In one embodiment, the genetic marker is selected from the group consisting of Chr6_88977023, Chr6_88612186, Chr6_88610743, Chr6_88977023, Chr6_88977023, Chr6_88326504, Chr6_88326504, Chr6_88326504 and Chr6_88326504 (cf. table 12), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as indicated in table 12. In one embodiment, the marker is Chr6_89059253 and the allele associated with mastitis resistance is the G-allele.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000018531, ENSBTAG00000009310, ENSBTAG00000016795, ENSBTAG00000008577, ENSBTAG00000016290, ENSBTAG00000012397, ENSBTAG00000002348, ENSBTAG00000013718, ENSBTAG00000009070 and ENSBTAG00000006507, cf. table 14.

BTA7

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA7 in a region delineated by BovineHD Genotyping BeadChip SNP#2907 and SNP#4789 and/or in a region between base nos. 14485587 and 22681472, for example, the marker is BovineHD0700005054 or is BovineHD Genotyping BeadChip SNP#18032163, or is linked to any of said markers.

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA7 in a region delineated by BovineHD Genotyping BeadChip SNP#7174 and SNP#10157 and/or in a region between base nos. 31432538 and 41607314, for example, the marker is BovineHD4100005904 or is BovineHD Genotyping BeadChip SNP#33485418, or is linked to any of said markers.

BTA12

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA12 in a region delineated by BovineHD Genotyping BeadChip SNP#787 and SNP#933 and/or in a region between base nos. 2569573 and 2991581, for example, the marker is BovineHD1200000926 or is BovineHD Genotyping BeadChip SNP#2917822, or is linked to any of said markers.

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA12 in a region delineated by BovineHD Genotyping BeadChip SNP#3217 and SNP#7626 and/or in a region between base nos. 11578657 and 27097379, for example, the marker is BovineHD1200006858 or is BovineHD Genotyping BeadChip SNP#22865273, or is linked to any of said markers.

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA12 in a region delineated by BovineHD Genotyping BeadChip SNP#15918 and SNP#17398 and/or in a region between base nos. 62561736 and 68494212, for example, the marker is BovineHD1200017277 or is BovineHD Genotyping BeadChip SNP#63068164, or is linked to any of said markers.

BTA13

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA13 in a region delineated by BovineHD Genotyping BeadChip SNP#11798 and SNP#15089 and/or in a region between base nos. 53471793 and 70173150, for example, the marker is BovineHD1300017074 or is BovineHD Genotyping BeadChip SNP#59588546, or is linked to any of said markers.

In one embodiment, the genetic marker is located on the bovine chromosome BTA13 in a region between 57-63 Mb, for example the marker is Chr13_57608628 and/or the trait is mastitis resistance, such as CM. In one embodiment, the genetic marker is selected from the group consisting of Chr13_57608336, Chr13_57608354, Chr13_59584651, Chr13_59584651, Chr13_57608628, Chr13_57608354, Chr13_60621602, Chr13_60621602 and Chr13_60621602 (cf. table 15), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as

indicated in table 15. In one embodiment, the marker is Chr13_57579568 and the allele associated with mastitis resistance is the T-allele, and/or the marker is Chr13_57579569 and the allele associated with mastitis resistance is the G-allele.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000020261, ENSBTAG00000012109, ENSBTAG00000018053, ENSBTAG00000018418, ENSBTAG00000013330, ENSBTAG00000048288, ENSBTAG00000003364, ENSBTAG00000048009, ENSBTAG00000027384, ENSBTAG00000027383, ENSBTAG00000020555, ENSBTAG00000031254, ENSBTAG00000016169, ENSBTAG00000016348, ENSBTAG00000019200, ENSBTAG00000010112, ENSBTAG00000038687 and ENSBTAG00000038412, cf. table 17.

BTA16

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA16 in a region delineated by BovineHD Genotyping BeadChip SNP#5299 and SNP#16175 and/or in a region between base nos. 21799660 and 64955150, for example, the marker is BovineHD1600014622 or is BovineHD Genotyping BeadChip SNP#52924145, or is linked to any of said markers.

In one embodiment, the genetic marker is located on the bovine chromosome BTA16 in a region between 48-55 Mb, for example the marker is Chr16_50529178 and/or the trait is mastitis resistance, such as CM11. In one embodiment, the genetic marker is selected from the group consisting of Chr16_50529178, Chr16_49054912, Chr16_49054912, Chr16_54246279, Chr16_50532600, Chr16_52097973, Chr16_53806663, Chr16_53806663 and Chr16_53998150 (cf. table 18), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as indicated in table 18. In one embodiment, the marker is Chr16_50529178 and the allele associated with mastitis resistance is the A-allele, and/or the marker is Chr16_50564280 and the allele associated with mastitis resistance is the T-allele.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000024663, ENSBTAG00000016057, ENSBTAG00000010732,

ENSBTAG00000015635, ENSBTAG00000015632, ENSBTAG00000014707, ENSBTAG00000014537 and ENSBTAG00000037523, cf. table 20.

BTA18

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA18 in a region delineated by BovineHD Genotyping BeadChip SNP#11892 and SNP#13902 and/or in a region between base nos. 41653211 and 48570545, for example, the marker is BovineHD1800013234 or is BovineHD Genotyping BeadChip SNP#44778431, or is linked to any of said markers.

BTA19

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA19 in a region delineated by BovineHD Genotyping BeadChip SNP#12750 and SNP#16762 and/or in a region between base nos. 49013784 and 62339802, for example, the marker is BovineHD1900015719 or is BovineHD Genotyping BeadChip SNP#55615219, or is linked to any of said markers.

In one embodiment, the genetic marker is located on the bovine chromosome BTA19 in a region between 55-58 Mb, for example the marker is Chr19_55296191 and/or the trait is mastitis resistance, such as SCS3. In one embodiment, the genetic marker is selected from the group consisting of Chr19_57164311, Chr19_55461224, BovineHD1900015719, Chr19_57418222, BovineHD1900015719, Chr19_55296191, Chr19_55296191, Chr19_55296191 and Chr19_55296191 (cf. table 21), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as indicated in table 21.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000013677, ENSBTAG00000005104 and ENSBTAG00000044443; cf. table 22.

BTA20

In another embodiment of the invention the at least one genetic marker is located on the bovine chromosome BTA20 in a region delineated by BovineHD Genotyping BeadChip SNP#7852 and SNP#14407 and/or in a region between base nos. 28291423 and 55744850, for example, the marker

is BovineHD2000010279 or is BovineHD Genotyping BeadChip SNP#35981673, or is linked to any of said markers.

In one embodiment, the genetic marker is located on the bovine chromosome BTA20 in a region between 32-40 Mb, for example the marker is Chr20_35965955 and/or the trait is mastitis resistance, such as CM2. In one embodiment, the genetic marker is selected from the group consisting of Chr20_34269660, Chr20_35965955, Chr20_35965955, Chr20_35914181, Chr20_35965955, Chr20_35969130, Chr20_35865606, Chr20_35914086 and Chr20_35543794 (cf. table 23), and/or the genetic marker allele associated with increased mastitis resistance, and/or the specific trait is as indicated in table 23. In one embodiment, the marker is Chr20_35965955 and the allele associated with mastitis resistance is the A-allele.

In one embodiment, the genetic marker is located in a gene selected from the group consisting of ENSBTAG00000010423, ENSBTAG00000014972, ENSBTAG00000016149, ENSBTAG00000006697, ENSBTAG000000033107, ENSBTAG00000011766 and ENSBTAG00000014177, cf. table 25.

In one specific embodiment, the at least one genetic marker is located in the Caspase recruitment domain-containing protein 6 gene (CARD6) on BTA20. Thus, in one preferred embodiment, the genetic marker associated with at least one trait indicative of mastitis, such as clinical mastitis, for example CM11, is located in the CARD6 gene, in particular in the coding region of NPFFR2. In one embodiment, the genetic marker associated with one or more mastitis traits is the rs133218364 SNP, which is located in the CARD6 gene on BTA20; cf. SEQ ID NO: 2. This SNP is a T-C substitution. However, as alternative SNPs located within the CARD6 gene are strongly coupled to the rs133218364 SNP, any genetic marker polymorphism located in the CARD6 gene is associated with a trait indicative of mastitis. Thus, the present invention relates to methods of determining mastitis and/or a breeding value as well as methods for selected cattle for breeding, and kits, wherein the at least one genetic marker is located in the CARD6 gene or is genetically coupled to the CARD6 gene, and in one preferred embodiment, the at least one genetic marker is the rs133218364 SNP and/or any genetic marker polymorphism genetically coupled thereto. Thus, in one embodiment, the genetic marker is the T/C SNP located in the CARD6 gene, wherein the T allele is associated with mastitis and the C allele is associated with resistance to mastitis.

In another specific embodiment, the at least one genetic marker is located in the Leukemia inhibitory factor receptor gene (LIFR) on BTA20, or the flanking sequences thereof, such as 5000 bp upstream or downstream of the LIFR gene. In one preferred embodiment, the genetic marker associated with at least one trait indicative of mastitis, such as clinical mastitis, for example CM11, is located in the LIFR gene or the flanking sequences, in particular within 5000 bp downstream of the LIFR gene coding region. In one embodiment, the genetic marker associated with one or more mastitis traits is the rs133596506 SNP, which is located 3323 bp downstream of the LIFR gene on BTA20; cf. SEQ ID NO: 3. This SNP is a T-C substitution. However, as alternative SNPs located within the LIFR gene and its flanking regions are strongly coupled to the rs133596506 SNP, any genetic marker polymorphism located in the LIFR gene and its flanking regions is associated with a trait indicative of mastitis. Thus, the present invention relates to methods of determining mastitis and/or a breeding value as well as methods for selected cattle for breeding, and kits, wherein the at least one genetic marker is located in the LIFR gene or its flanking regions is genetically coupled to the LIFR gene, and in one preferred embodiment, the at least one genetic marker is the rs133596506 SNP and/or any genetic marker polymorphism genetically coupled thereto. Thus, in one embodiment, the genetic marker is the T/C SNP located in the LIFR gene or its flanking regions, wherein the C allele is associated with mastitis and the T allele is associated with resistance to mastitis.

Detection

The method according to the present invention for determining mastitis resistance of a bovine subject comprises detecting in a sample from said bovine subject the presence or absence of at least one genetic marker allele that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom. Specific genetic markers associated with mastitis resistance are provided elsewhere herein. The genetic markers, including microsatellite markers and/or SNPs, or a complementary sequence as well as transcriptional (mRNA) and translational products (polypeptides, proteins) therefrom may be identified by any method known to those of skill within the art.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more of positions mentioned herein in the specified region. Mutations or polymorphisms within or flanking the spec-

ified region can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures that are well known to those of skill in the art. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and a signal generation system.

A number of mutation detection techniques are listed below. Some of the methods listed are based on the polymerase chain reaction (PCR), wherein the method according to the present invention includes a step for amplification of the nucleotide sequence of interest in the presence of primers based on the nucleotide sequence of the variable nucleotide sequence. The methods may be used in combination with a number of signal generation systems, a selection of which is listed further below.

General techniques	DNA sequencing, Sequencing by hybridisation, SNAP-shot
Scanning techniques	Single-strand conformation polymorphism analysis, Denaturing gradient gel electrophoresis, Temperature gradient gel electrophoresis, Chemical mismatch cleavage, cleavage, heteroduplex analysis, enzymatic mismatch cleavage
Hybridisation based techniques	Solid phase hybridisation: Dot blots, Multiple allele specific diagnostic assay (MASDA), Reverse dot blots, Oligonucleotide arrays (DNA Chips) Solution phase hybridisation: Taqman -U.S. Pat. No. 5,210,015 & 5,487,972 (Hoffmann-La Roche), Molecular Beacons – Tyagi et al (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York), Lightcycler, optionally in combination with Fluorescence resonance energy transfer (FRET).
Extension based tech-	Amplification refractory mutation system (ARMS), Ampli-

niques	fication refractory mutation system linear extension (ALEX) - European Patent No. EP 332435 B1 (Zeneca Limited), Competitive oligonucleotide priming system (COPS) - Gibbs et al (1989), Nucleic Acids Research, 17, 2347.
Incorporation based techniques	Mini-sequencing, Arrayed primer extension (APEX)
Restriction Enzyme based techniques	Restriction fragment length polymorphism (RFLP), Restriction site generating PCR
Ligation based techniques	Oligonucleotide ligation assay (OLA)
Other	Invader assay
Various Signal Generation or Detection Systems	Fluorescence: Fluorescence resonance energy transfer (FRET), Fluorescence quenching, Fluorescence polarisation--United Kingdom Patent No. 2228998 (Zeneca Limited)
Other	Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Further amplification techniques are found elsewhere herein. Many current methods for the detection of allelic variation are reviewed by Nollau et al., Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

The detection of genetic markers can according to one embodiment of the present invention be achieved by a number of techniques known to the skilled person, including typing of microsatellites or short tandem repeats (STR), restriction fragment length polymorphisms (RFLP), detection of deletions or insertions, random amplified polymorphic DNA (RAPIDs) or the typing of single nucleotide polymorphisms by methods such as restriction fragment length polymerase chain reaction, allele-specific oli-

gomer hybridisation, oligomer-specific ligation assays, hybridisation with PNA or locked nucleic acids (LNA) probes.

In one embodiment, the methods of the invention comprise amplifying a genetic region comprised in the sample provided from the bovine subject. Thus, specific methods may include amplifying a genetic region comprising a genetic marker of the invention, and detecting that amplification product.

In another preferred embodiment, the genetic marker is detected by DNA array methods. It is, for example, possible to genotype large numbers of SNP markers simultaneously using commercially available SNP genotyping kits. Such kits are for example the bovineSNP50 beadchip SNP kit provided by Illumina Inc., and the BovineHD BeadChip from Illumina Inc. Both of these kits are preferred for SNP genotyping according to the present invention.

A primer of the present invention is a nucleic acid molecule sufficiently complementary to the sequence on which it is based and of sufficiently length to selectively hybridise to the corresponding region of a nucleic acid molecule intended to be amplified. The primer is able to prime the synthesis of the corresponding region of the intended nucleic acid molecule in the methods described above. Similarly, a probe of the present invention is a molecule for example a nucleic acid molecule of sufficient length and sufficiently complementary to the nucleic acid sequence of interest which selectively binds to the nucleic acid sequence of interest under high or low stringency conditions. The genetic marker associated with mastitis resistance according to the present invention can be detected by a number of methods known to those of skill within the art. For example, the genetic marker may be identified by genotyping using a method selected from the group consisting of single nucleotide polymorphisms (SNPs), microsatellite markers, restriction fragment length polymorphisms (RFLPs), DNA chips, amplified fragment length polymorphisms (AFLPs), randomly amplified polymorphic sequences (RAPDs), sequence characterised amplified regions (SCARs), cleaved amplified polymorphic sequences (CAPSs), nucleic acid sequencing, and microsatellite genotyping.

In a preferred embodiment, the genetic markers associated with mastitis resistance traits as disclosed in the present invention is detected by SNP or microsatellite genotyping. SNP or microsatellite genotyping may be performed by amplification of the SNP or microsatellite marker by sequence

specific oligonucleotide primers, and subsequent analysis of the amplification product, in terms of for example length, quantity and/or sequence of the amplification product.

Specifically, the at least one genetic marker according to the present invention may be detected by use of at least one oligonucleotide comprising between 5 and 100 consecutive nucleotides, such as between 10 and 30 consecutive nucleotides, or at least 5, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or at least 25 consecutive nucleotides of the NPFFR2 gene, such as SEQ ID NO: 1, or a nucleic acid sequence at least 70% identical thereto, such as at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, such as at least 99% thereto.

In one embodiment of the methods and kits of the present invention, the genetic marker is detected by using an oligonucleotide primer or probe capable of recognizing at least one SNP selected from the group of SNPs set forth in column 10 of table 2. The oligonucleotide may be used as a primer in a nucleic acid amplification reaction and/or the oligonucleotide may be used as a probe in a hybridization detection technique.

The primers of the present invention may be used individually or in combination with one or more primers or primer pairs, such as any primer of the present invention.

The design of such primers or probes will be apparent to the molecular biologist of ordinary skill. Such primers are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such primers will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the region. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The primers/probes of the invention may carry one or more labels to facilitate detection.

In one embodiment, the primers and/or probes are capable of hybridizing to and/or amplifying a subsequence hybridizing to a single nucleotide polymorphism containing the sequence delineated by the markers as shown herein.

The primer nucleotide sequences of the invention further include: (a) any nucleotide sequence that hybridizes to a nucleic acid molecule comprising a genetic marker sequence or its complementary sequence or RNA products under stringent conditions, e.g., hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2x SSC/0.1% Sodium Dodecyl Sulfate (SDS) at about 50-65°C, or (b) under highly stringent conditions, e.g., hybridization to filter-bound nucleic acid in 6x SSC at about 45°C followed by one or more washes in 0.1x SSC/0.2% SDS at about 68°C, or under other hybridization conditions which are apparent to those of skill in the art (see, for example, Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at pp. 6.3.1-6.3.6 and 2.10.3). Preferably the nucleic acid molecule that hybridizes to the nucleotide sequence of (a) and (b), above, is one that comprises the complement of a nucleic acid molecule of the genomic DNA comprising the genetic marker sequence or a complementary sequence or RNA product thereof.

Among the nucleic acid molecules of the invention are deoxyoligonucleotides ("oligos") which hybridize under highly stringent or stringent conditions to the nucleic acid molecules described above. In general, for probes between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula:

$$T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log [\text{monovalent cations (molar)}]) + 0.41(\% \text{ G+C}) - (500/N)$$

where N is the length of the probe. If the hybridization is carried out in a solution containing formamide, the melting temperature is calculated using the equation $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log [\text{monovalent cations (molar)}]) + 0.41(\% \text{ G+C}) - (0.61\% \text{ formamide}) - (500/N)$ where N is the length of the probe. In general, hybridization is carried out at about 20-25 degrees below T_m (for DNA-DNA hybrids) or 10-15 degrees below T_m (for RNA-DNA hybrids).

Exemplary highly stringent conditions may refer, e.g., to washing in 6x SSC/0.05% sodium pyrophosphate at 37°C (for about 14-base oligos), 48°C (for about 17-base oligos), 55°C (for about 20-base oligos), and 60°C (for about 23-base oligos).

Accordingly, the invention further provides nucleotide primers or probes which detect the polymorphisms of the invention. The assessment may be conducted by means of at least one nucleic acid primer or probe, such as a primer or probe of DNA, RNA or a nucleic acid analogue such as peptide nucleic acid (PNA) or locked nucleic acid (LNA).

According to one aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a polymorphism at one or more of positions in the delineated regions.

The allele-specific oligonucleotide probe is preferably 5-50 nucleotides, more preferably about 5-35 nucleotides, more preferably about 5-30 nucleotides, more preferably at least 9 nucleotides.

Determination of association with mastitis

In order to detect if a genetic marker is present in the genetic material, standard methods well known to persons skilled in the art may be applied, e.g. by the use of nucleic acid amplification. In order to determine if the genetic marker is genetically linked to mastitis resistance traits, a permutation test can be applied (Doerge and Churchill, 1996), or the Piepho-method can be applied (Piepho, 2001). The principle of the permutation test is well described by Doerge and Churchill (1996), whereas the Piepho-method is well described by Piepho (2001). Significant linkage in the within family analysis using the regression method, a 10000 permutations were made using the permutation test (Doerge and Churchill, 1996). A threshold at the 5% chromosome wide level was considered to be significant evidence for linkage between the genetic marker and the mastitis resistance and somatic cell count traits. In addition, the QTL was confirmed in different sire families. For the across family analysis and multi-trait analysis with the variance component method, the Piepho-method was used to determine the significance level (Piepho, 2001). A threshold at the 5% chromosome wide level was considered to be significant evidence for linkage between the genetic marker and the mastitis resistance and somatic cell count traits.

Method for selecting a bovine subject

In one aspect, the present invention further relates to a method for selecting a bovine subject for breeding purposes. This method for selecting a bovine subject for breeding purposes comprises determining resistance to mastitis of said bovine subject and/or off-spring therefrom by any method as defined herein, such as determining resistance to mastitis in a bovine subject, by detecting in a

sample from said bovine subject the presence or absence of at least one genetic marker as defined herein.

The purpose of the method is to select those bovine subjects with the best breeding value for breeding. For example, selection of bovine subjects for breeding according to the present invention serve to increase the mean breeding value of the next generation of bovine subjects, compared to the mean breeding value of the previous (parent) generation of bovine subjects.

In one embodiment, the method of the present invention for selecting a bovine subject for breeding purposes comprises estimating a breeding value of said selected bovine subject. For example, the breeding value is estimated on the basis of the presence or absence of a genetic marker of the present invention.

Kit

In one aspect, the present invention relates to a kit, such as a diagnostic kit, for detecting the presence or absence in a bovine subject of at least one genetic marker as described herein, such as a marker associated with resistance to mastitis. In one embodiment, the present invention relates to a diagnostic kit for detecting the presence or absence in a bovine subject of two or more genetic marker alleles as described elsewhere herein, said kit comprising at least one detection member. Specifically, the kit is suitable for detection of the presence or absence of at least one genetic marker allele, such as two or more genetic markers, which are associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom. Examples of specific traits which are indicative of mastitis resistance are disclosed elsewhere herein. Such traits include, SCS, SCC, and treated cases of clinical mastitis, for example CM11, CM12, CM2, CM3, CM, SCC3, SCC2, SCC1 and/or SCC.

The kit of the invention preferably comprise at least one detection member for determining a genetic marker located in a genomic region as defined herein above.

Detection members of the present invention include any entity, which is suitable for detecting a genetic marker on the genomic (including epigenomic), transcriptional or translational level. Detection members comprise oligonucleotide primers and/or probes, antibodies, aptamers, chemical substances etc.

In one embodiment, the diagnostic kit comprises at least one oligonucleotide for detecting said genetic marker allele in said bovine subject.

In one embodiment, the detection member is an oligonucleotide primer and/or an oligonucleotide probe. In a preferred embodiment, the detection member is an oligonucleotide primer as described elsewhere herein, or an oligonucleotide probe with a sequence corresponding to any oligonucleotide primer as defined herein. The at least one oligonucleotide of the kit preferably comprises or consists of between 5 and 100 consecutive nucleotides, such as between 10 and 30 consecutive nucleotides, or at least 5, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or at least 25 consecutive nucleotides. In a preferred embodiment, the detection member is an oligonucleotide comprising at least 5 consecutive nucleotides specific for any one of the SNP markers set forth in columns 9 and 10 in the table identified in table 2.

In one aspect, the present invention relates to a kit for use in detecting the presence or absence in a bovine subject of at least one genetic marker associated with resistance to mastitis, comprising at least one detection member for determining a genetic marker located in a region of the bovine genome selected from the group consisting of regions 1-61 of table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6.

The genetic markers to be detected by the detection members of the kit of the present invention are disclosed elsewhere herein. Thus, the genetic marker is for example any genetic marker as described herein, such as two or more genetic marker alleles located in a gene selected from the group consisting of the markers mentioned in columns 9 and 10 of table 2. In a preferred embodiment, the genetic marker is located in the NPFFR2 gene, as defined elsewhere herein. Thus, in one embodiment, the kit of the invention comprise at least one detected member capable of detecting a mutation in the NPFFR2 gene, in particular for detecting the chr6_89059253 SNP located at 89,059,253 Bp position on BTA6. The detection member, thus in a preferred embodiment is a nucleic acid sequence comprising between 5 and 100 consecutive nucleotides, such as between 10 and 30 consecutive nucleotides, or at least 5, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or at least 25 consecutive nucleotides of the NPFFR2 gene, such as SEQ ID NO: 1, or a nucleic acid sequence at least 70% identical thereto, such as at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,

90, 91, 92, 93, 94, 95, 96, 97, 98, such as at least 99% thereto. In a preferred embodiment, the nucleic acid sequence comprises the chr6_89059253 SNP, and/or any genetic marker polymorphism coupled thereto.

The kits of the present invention may further comprise at least one reference sample. In one embodiment, said reference sample comprises a nucleic acid sequence comprising a genetic marker associated with mastitis resistance, such as described herein, and in another embodiment, the reference sample comprises a nucleic acid sequence comprising a genetic marker associated with susceptibility to mastitis

The kits of the present invention further comprise in specific embodiments instructions for performance of the detection method of the kit and for the interpretation of the results.

Genotyping of a bovine subject in order to establish the genetic determinants of resistance to mastitis for that subject according to the present invention can be based on the analysis of DNA and/or RNA. One example is genomic DNA which can be provided using standard DNA extraction methods as described herein. The genomic DNA may be isolated and amplified using standard techniques such as the polymerase chain reaction using oligonucleotide primers corresponding (complementary) to the polymorphic marker regions. Additional steps of purifying the DNA prior to amplification reaction may be included. Thus, a diagnostic kit for establishing mastitis resistance and somatic cell count characteristics comprises, in a separate packing, at least one oligonucleotide sequence.

The invention also relates to the use of a kit of the invention for detecting the presence or absence in a bovine subject of at least one genetic marker associated with resistance to mastitis, in particular for detecting any one or more of the markers identified herein. Furthermore, the present invention relates to the use of a kit of the present invention for estimating breeding value in respect of susceptibility to mastitis in a bovine subject.

Method of estimating breeding value

The present invention also relates to determination of estimated breeding values.

In a large randomly mated population, each individual should on average give birth to two offspring in order to maintain the size of the population. The distribution of the number of offspring in the popula-

tion has a left skewed binominal distribution (Poisson distributed) with an average value of 2 and variance of 2. Which means that the number of offspring per individual can vary from 0 and upwards, the values 0,1,2,3,4 and 5 being the most frequent. An estimated breeding value is often called an index (I). The index can be estimated on the basis of information of phenotype values from all possible relatives. A simple regression line or multiple regression can be used. The higher the number of relatives is the better the estimation will be. Correlation between the true breeding value (A) and the index is given the name Accuracy and it has the symbol r_{AI} . The estimated breeding value is based on a theory of linear regression and correlation.

In one aspect, the present invention relates to a method for estimating a breeding value in respect of susceptibility to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom, wherein said at least one genetic marker is located in a region of the bovine genome selected from the group consisting of regions 1-61 of table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6. The method preferably comprises detection of one or more of the specific markers associated with mastitis, which are identified elsewhere herein.

The breeding value is in one example determined using a multi-trait random regression model (mt-RRM) combined longitudinal TDSCS and binary CM traits, for example having the general description of the model in matrix form:

$$\mathbf{y} = \mathbf{X}\mathbf{b} + \mathbf{H}_h\mathbf{h} + \mathbf{K}_k\mathbf{k} + \mathbf{Z}_a\mathbf{a} + \mathbf{Z}_p\mathbf{p} + \mathbf{e} ,$$

where: $\mathbf{y}$ is a vector with observations on the nine different traits explained above. Vectors $\mathbf{b}$, $\mathbf{h}$, $\mathbf{k}$ contain the environmental effects whilst vectors $\mathbf{a}$, and $\mathbf{p}$ contain additive genetic and nongenetic animal regression coefficients, respectively.

Environmental effects in the model could be calving age, herd environment and stage of lactation. Both additive genetic and non-genetic animal effects can be modelled by a second order Legendre polynomial for TDSCS and intercept for the other traits leading to a 15×15 (co)variance matrix for each random effect to be estimated. Vector $\mathbf{e}$ contains the residuals of the 9 traits.

In order to facilitate accurate estimation, residual (co)variances between CM traits and TDSCS may be assumed to be zero and the residual variance of CM and udder type traits may be set to operationally low values so that part of this variance entered the permanent environmental component. This can facilitate estimation of permanent environmental correlation between CM and the longitudinal trait. The covariance components were estimated using DMU package.

In one embodiment, the breeding value is calculated using a marker-assisted single trait Best Linear Unbiased Prediction (MA-BLUP).

The specific mastitis resistances traits, genetic markers and marker alleles, samples, bovine subjects, detection methods etc. are defined elsewhere herein.

Selective breeding

In one aspect, the present invention provides a method for selective breeding of bovine subjects. The method of the invention allows the identification of bovine subjects suitable for selective breeding.

In one embodiment these methods comprise the steps of

- a. providing a bovine subject,
- b. obtaining a biological sample from said subject,
- c. determining the presence in that sample of at least one genetic marker located in a region of the bovine genome selected from the group consisting of regions 1-61 of table 2, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6,
- d. selecting a bovine subject having in its genome said at least one genetic marker, and
- e. using said bovine subject for breeding.

The biological sample could be any suitable sample comprising genetic material, and which is preferably easily obtainable. Sample types are described further elsewhere herein.

The bovine is preferably a male subject, i.e. a bull. For example, when the bovine subject is a bull, the use of the bovine subject for breeding would normally include collecting semen from said bull and using said semen for artificial insemination of one or more heifers or cows.

However, the presence of the relevant genetic marker(s) may also be determined in cows and heifers according to the method of the invention.

Examples

Example 1

Fine-mapping of clinical mastitis and somatic cell score QTL in dairy cattle

Introduction

Genome-wide linkage analysis was until recently the method of choice for quantitative trait loci (QTL) genome scan in cattle due to availability of large half-sib family structure. Linkage analysis is the method traditionally used to identify genes for phenotypes exhibiting Mendelian inheritance. For complex phenotypes such as quantitative traits, linkage analysis has only had limited success. In linkage analysis there are a few opportunities for recombination to occur within families and pedigree with known ancestry, resulting in relatively low mapping resolution which limits the candidate polymorphism search. In the contrary, association mapping (linkage disequilibrium mapping) has emerged as a powerful tool to resolve complex trait variation down to the sequence level by exploiting historical recombination events at the population level for high resolution mapping. In this approach markers/haplotypes with predicting ability in the general population for a trait of interest are identified. Such markers and haplotypes could be used directly for marker-based selection. Typically genome scans are used to map QTL for which some test statistic exceeds a pre-defined threshold value. Although the threshold level can be chosen to be very conservative, a probability that the QTL in reality represents a type I error remains. Therefore, results from QTL studies should be confirmed in an independent analysis before being used in subsequent fine mapping experiments or in marker-assisted selection. If the results from linkage analysis can be confirmed by an association study, it will also provide credibility to the detected QTL.

Lund et al (2008) mapped QTL for clinical mastitis and somatic cell score in Danish Holstein cattle using linkage analysis. These authors used data on 356 microsatellite markers spread across all auto-

somes with an average marker spacing of 8.6 cM. Nonetheless, the QTL regions reported were quite long (more than 20 cM for some QTL). Such large QTL regions along with family-specific marker-QTL associations limit the usability of their result for practical animal breeding as well as for candidate polymorphism searches. Thus, a need to map QTL to narrower genomic regions remains because inclusion of QTL information in selection decisions requires fine-mapping of causal polymorphisms. In this example, association mapping was carried out for 6 mastitis traits in cattle using dense SNP markers.

Materials and Methods

Genotyping

A total of 2,531 Danish and Swedish Holstein bulls were genotyped using the bovineSNP50 beadchip (Illumina®). Only SNPs with minor allele frequency equal to or higher than 0.05 and average GC score of at least 0.65 were retained for the analysis. Thus total of 36,387 SNPs on 29 bovine autosomes (BTAs) were selected for association analyses. Individual SNP types with GC score less than 0.6 were dropped. The number of SNPs included for analysis varied from 675 on BTA28 to 2,320 on BTA1. The details on the genotyping platform and quality control for SNPs are described by Sahana et al. (2010a). The SNP positions within a chromosome were based on the *Bos taurus* genome assembly (*Btau_4.0*, Liu et al. 2009).

Phenotypic data

Single trait breeding values (STBV) were used as phenotypes in this analysis. Six mastitis related STBVs were analyzed for association with SNPs. Single-trait breeding values were calculated for each animal using best linear unbiased prediction (BLUP) procedures and a sire model by the Nordic Cattle Genetic Evaluation. For definitions and models used in breeding value prediction, see <http://www.nordicebv.info>, except that the correlation to other traits was set to 0 to avoid information from phenotypes of correlated traits to affect results of any particular trait. Also, only sire-son and son-offspring relationships were included, effectively producing a sire model. The STBV were adjusted for the same systematic environmental effects as in the official routine evaluations. Clinical mastitis was defined as a binary trait, mastitis treatment (1) or not (0) within four time periods: the incidence of mastitis from -15 to 50 days in first lactation (CM11), 51 to 305 days in first lactation (CM12), -15 to 305 days in second lactation (CM2), -15 to 305 days in third lactation (CM3), all measure as binary trait. The STBVs for the four mastitis traits are weighted together by the following relative weights: $CM = 0.25 \cdot CM11 + 0.25 \cdot CM12 + 0.3 \cdot CM2 + 0.2 \cdot CM3$ to form a mastitis resistance index (CM) (Johansson

et al. 2007), standardized to a mean of 100 and a standard deviation of 10. Somatic cell score (SCS) is an important trait for the estimation of breeding values for udder health. SCS is an index of average log somatic cell count from 5 to 170 days from first three lactations with relative weights of 0.5, 0.3 and 0.2 for first, second and third lactation respectively (Johansson et al. 2007). The number of STBVs available for analysis among the genotyped animals were 1671 for CM11, CM12 1668, CM2 1669, CM3 1544, CM 2098 and SCS 1671.

Statistical Methods for association analysis

Mixed model: The mixed model analysis as proposed by Yu et al. (2006) was used for association analyses. In this approach, a polygenic genetic effect was fitted as a random effect. Single SNPs were successively included as fixed effect in the model. The model was:

$$\mathbf{y} = \mu \mathbf{1} + \alpha \mathbf{s} + \mathbf{Z}\mathbf{u} + \mathbf{e}$$

where $\mathbf{y}$ is a vector of observed phenotypes (STBV), μ is a shared fixed effect, $\mathbf{1}$ is a vector of ones, α is allele substitution effect of the SNP, $\mathbf{s}$ is an incidence vector with elements 0, 1 or 2 relating α to the individuals, $\mathbf{Z}$ is a matrix relating records to individuals, $\mathbf{u}$ is a vector of additive polygenic effects and $\mathbf{e}$ is a vector of random residual effects. The random variables $\mathbf{u}$, and $\mathbf{e}$ are assumed to be multivariate normally distributed. $\mathbf{u}$ has mean $\mathbf{0}$ and covariance matrix $\sigma_g^2 \mathbf{A}$, where σ_g^2 is the polygenic genetic variance and $\mathbf{A}$ is the additive relationship matrix derived from pedigree. $\mathbf{e}$ has mean 0 and covariance matrix $\sigma_e^2 \mathbf{I}$, where σ_e^2 is the residual variance and $\mathbf{I}$ is the identity matrix. The analysis was carried out using the software package DMU (<http://gbi.agrsci.dk/dmu/>). Significance of each marker's effect was tested using a t-test against a null hypothesis of $\alpha=0$.

Significance test: For control of the family-wise error rate (FWER), the Bonferroni correction was applied. The Bonferroni correction controls FWER (α) = $1-(1-\alpha_i)^m \approx \alpha_i m$, where α_i is the individual test rejection level and m is the number of tests. The 5% chromosome-wise significance thresholds ranged from the point wise p-value of 2.16×10^{-5} on BTA1 to 7.41×10^{-5} on BTA28, or 4.67 to 4.13 in the $-\log_{10}$ transformed scale. Bonferroni correction is very conservative (Han et al. 2009) as it does not take account of correlation (linkage disequilibrium) among SNPs. We used a liberal significance threshold of 10^{-4} for the QTL regions where QTL have previously been identified by Lund et al. (2008) who used linkage analyses with microsatellite markers for QTL mapping. In the following sections a significant association will mean chromosome-wise significant, and a suggestive association means a point wise p-value less than 10^{-4} .

Marking the QTL region: Normally multiple SNPs in the vicinity of a QTL are expected to yield significant results in a single SNP analysis. This is because all SNPs that are physically located near the causal factor will tend to be in linkage disequilibrium. This effect declines with genetic distance and also depends on minor allele frequencies. In this study, QTL regions were demarcated subjectively. Starting at the most significant SNP, the QTL region was extended left and right until a region was reached where all markers had $-\log(p)$ values below 3. I.e. that the QTL thus demarcated may contain one or more non-significant markers. To compare results from the present study with the earlier ones, we took the maker positions from *Btau_4.0*. If the maker location was not available in *Btau_4.0*, we have reported marker and given the position in cM from MARC table [<http://www.marc.usda.gov/genome/cattle/cattle.html>].

Results

The present genome-wide association study (GWAS) identified 9 chromosome-wise significant QTL for clinical mastitis and somatic cell score on 8 chromosomes in Danish and Swedish Holstein cattle (Table 3). We have presented 92 SNP x trait combinations which showed chromosome-wise significant association and out of then 24 combinations crossed genome-wide significance threshold (Supplementary Table 3). Most of the genome-wide significant associations were observed for CM and four SNP showed genome-wide significant association with CM2. Five SNPs showed significant association with more than one mastitis trait. The signal plots (Figure 1 to 6) give an overview how the SNPs association are located across the genome and also help to visualize if the QTL on the genome location affecting more than one trait. The most highly significant signal was observed on BTA6. Here a highly significant association with several mastitis traits was observed. The strongest signal was for CM followed by CM2, SCS and CM11. Consistent results across traits for association were observed on BTA16 for SCS, CM11, CM12, and CM, and on BTA1 for SCS, CM11, CM12, CM2 and CM. Confirmation of QTL at the same chromosomal locations across several mastitis traits was also observed on BTA14.

Table 3 Quantitative trait loci (QTL) detected by association analysis for mastitis traits with the most significant SNPs and the QTL region.

Chr.	QTL region (Mb)	Most significant SNP			Traits with significant/ suggestive
		Name	Pos (Bp)	$-\log_{10}(P)$	

					association
1	148.3 – 160.9	ss86284888	159167781	5.077	CM, CM11, CM2
4	14.0 – 25.7	rs41649041	19718653	5.292	CM, SCS
6	20.5 – 27.8	ss61565956	25195079	7.083	CM, CM2, SCS
6	85.0 – 90.7	ss86341106	89212073	9.535	CM, CM11, SCS
13	57.5 – 61.9	ss86317725	57728100	7.653	CM, CM11, CM12
14	0.1 – 2.8	ss86328358	679601	6.488	CM, CM2
16	46.3 – 55.1	rs41812941	50838131	5.735	CM, CM11, SCS
19	51.2 – 61.3	ss86327354	54763344	5.314	CM, CM12, CM2
20	34.1 – 44.3	rs41940571	37740343	7.786	CM, SCS

Table 4. SNP showing chromosome-wise significant association with mastitis traits. The genome-wide significant SNPs (which are preferred markers of the present invention) are in bold font.

		Position				
chr	SNP	(Bp)	Trait	alpha	se	-log ₁₀ (P)
1	ss86328743	150055732	CM	-0.783	0.170	5.01
1	rs41618669	157571776	CM2	0.244	0.053	4.95
1	ss86284888	159167781	CM	-0.893	0.192	5.08
1	rs41580905	160353510	CM	-2.522	0.543	5.07
4	rs41649041	19718653	CM	-1.543	0.324	5.29
6	rs43706944	20565525	CM2	-0.247	0.052	5.30
6	rs42189699	20586033	CM2	0.247	0.052	5.28
6	rs42553026	22210179	CM	-0.734	0.153	5.38
6	rs41664497	25195079	CM	-1.418	0.310	4.94
6	rs41664497	25195079	CM2	0.581	0.104	7.08
6	ss86290235	26706544	CM	0.885	0.176	5.90

46

6	ss86340493	27761080	CM	-0.698	0.159	4.57
6	ss86305923	27786722	CM	2.455	0.554	4.65
6	ss86330005	29212237	CM	-1.146	0.244	5.19
6	ss86340725	81134003	CM	0.760	0.172	4.62
6	rs29015635	81958670	CM	0.810	0.161	5.89
6	rs42895750	82226494	CM	1.350	0.303	4.71
6	ss117968104	84194536	CM	1.513	0.315	5.40
6	rs29017739	85040979	CM	-2.016	0.331	8.42
6	rs29001782	86128028	CM	0.949	0.154	8.55
6	rs41588957	86467725	CM	-0.837	0.156	6.62
6	ss86307579	87255541	CM	-0.883	0.160	6.98
6	ss86317213	87879378	CM	-0.788	0.156	5.90
6	rs41610991	87904281	CM	-0.880	0.154	7.44
6	ss117968170	88263655	CM	0.764	0.173	4.60
6	ss117968764	88326005	CM	0.720	0.151	5.29
6	ss117968030	88370145	CM	-1.418	0.319	4.67
6	ss117968525	88427760	CM	-0.724	0.159	4.87
6	rs29019575	88946762	CM	-0.891	0.192	5.07
6	ss117968738	88983536	CM	0.974	0.172	7.36
6	ss86326721	89030230	CM	0.691	0.157	4.57
6	ss86341106	89212073	cell	0.010	0.002	4.60
6	ss86341106	89212073	CM	-1.071	0.164	9.53
6	rs29010419	89274693	CM	-0.959	0.217	4.64
6	rs29022799	89603521	CM	1.183	0.248	5.31
6	ss86278591	89668441	CM	-2.444	0.468	6.29
6	ss86337596	89774923	CM	-0.972	0.152	9.22
6	rs43338539	89838828	CM	0.917	0.179	6.05
6	ss86296213	90008100	CM	1.144	0.190	8.18
6	rs42766480	90075264	CM	0.916	0.167	6.89
6	rs41617692	90670191	CM	-1.155	0.232	5.76
6	ss117963883	94872475	CM	-0.987	0.166	8.02
6	rs43475842	97726008	CM	-1.680	0.336	5.81

47

7	rs29019286	55023686	CM	-0.697	0.164	4.33
9	ss86292503	75920644	CM	0.757	0.169	4.75
13	ss86317725	57728100	CM	-0.858	0.148	7.65
13	ss86290731	57750019	CM	0.846	0.149	7.32
13	ss86332750	60565842	CM	0.683	0.149	4.94
13	ss86335834	61476511	CM	0.682	0.156	4.56
13	ss86340346	61851139	CM	-0.657	0.152	4.45
13	ss105239139	61885421	CM	-0.721	0.153	5.20
14	ss117971362	76704	CM2	0.246	0.052	5.23
14	ss86287919	236533	CM2	-0.282	0.054	6.25
14	ss86329615	443936	CM2	-0.278	0.054	6.09
14	ss86301882	596340	CM2	0.297	0.068	4.54
14	ss86328358	679601	CM2	-0.279	0.052	6.49
14	ss117971370	1461084	CM2	0.251	0.054	5.15
14	ss117971325	1490177	CM2	0.237	0.053	4.79
14	ss86339873	1913107	CM2	0.267	0.061	4.57
14	ss117971671	2757890	CM	-0.681	0.156	4.54
14	ss117971176	4477035	CM2	-0.246	0.057	4.41
16	rs41807595	41214862	CM12	0.269	0.056	5.39
16	rs41807595	41214862	CM11	0.191	0.039	5.49
16	rs29023167	44203083	CM	0.706	0.159	4.64
16	ss86303613	46324306	CM	-0.883	0.183	5.45
16	ss86283374	47856310	CM	0.882	0.206	4.38
16	ss86328473	47965588	CM	-0.895	0.204	4.58
16	ss86307986	48992727	CM	1.580	0.351	4.77
16	rs41603818	49348430	CM	-1.788	0.399	4.74
16	rs41812941	50838131	CM	0.786	0.158	5.73
16	ss105262977	54985553	cell	-0.012	0.003	4.54
16	ss105262977	54985553	CM	0.916	0.207	4.66
16	rs42465037	55087523	CM11	-0.386	0.080	5.48
19	ss86327354	54763344	CM	0.747	0.157	5.31
20	ss86327432	34080608	CM	-0.852	0.197	4.46

48

20	ss61484557	34367588	CM	-0.878	0.178	5.66
20	rs42329877	35113127	CM	0.980	0.204	5.38
20	ss86333005	35266596	CM	-0.765	0.179	4.36
20	ss86306906	35610598	CM	0.778	0.181	4.41
20	ss117972835	36202144	CM	-0.863	0.177	5.55
20	rs41938511	36232606	CM	-0.984	0.193	6.02
20	rs42542144	36520617	CM	-0.880	0.191	5.02
20	rs41940571	37740343	CM	1.127	0.193	7.79
20	rs41947330	37946352	CM	-0.879	0.179	5.64
20	rs29018751	39518858	CM	-0.884	0.204	4.45
20	rs41581087	39556494	CM	-0.823	0.187	4.60
20	ss105263178	41861300	CM	0.969	0.195	5.75
20	rs41641052	43585047	CM	-0.798	0.176	4.82
20	rs41641055	44311000	CM	-0.970	0.215	4.82
20	ss86292111	44333199	CM	-0.922	0.215	4.36
23	rs41600165	11692055	CM	-0.690	0.154	4.74
25	ss86306865	12503168	CM2	0.221	0.053	4.22

Discussion

The QTL intervals observed with association mapping were much narrower than those reported by Lund et al. (2008) who used linkage study with sparse map of microsatellite markers. Association mapping utilizes population level linkage disequilibrium. It therefore can map a QTL to a very small chromosomal region. The definitions of the mastitis traits were slightly different in Lund et al. (2008) and the present study. Thus, clinical mastitis for the first lactation (-10 to 305 d) was studied as one trait (CM1), while we have divided the first lactation mastitis into two sub-traits (CM11 and CM12). On BTA4, we detected a QTL affecting CM and SCS at 19.7 Mb. We further observed 3 SNPs between 66.46-66.61 Mb had $-\log_{10}(p)$ values between 3.5-3.8. We also detected two suggestive QTL for CM at 40.3 and 97.0 Mb on BTA5.

The strongest association of SNP to mastitis traits in this study was observed on BTA6 at 89.2Mb. This QTL affected CM, CM11 and SCS. The most significant SNP, ss86341106, is located within the gene Deoxycytidine kinase (DCK), which catalyzes the rate-determining step in the deoxyribonucleoside salvage pathway. The highest levels of DCK expression are found in thymus and bone marrow, which indicates a role of DCK in lymphopoiesis. Indeed, knockout mice lacking enzyme activity revealed a combined immune deficiency phenotype, i.e. they produce very low levels of both T and B lymphocytes (Toy et al., 2010). Another strong candidate gene in this region is the IGJ gene, which encodes the immunoglobulin J polypeptide. This protein serves a nucleating function in the formation of the immunoglobulin M (IgM) pentameric complex and in the assembly of IgA dimers and polymers. IgM is the first antibody produced in the primary immune response to microbial infections and therefore plays a crucial role in preventing systemic spread of the pathogen (Racine and Winslow, 2009). Also IgA is engaged in the defense against microorganisms, in particular those that invade the host through mucosal surfaces. Thus, IgA is the major antibody class found in mucosal secretions, where it combines with microbes to prevent them from attaching to or penetrating the mucosal membranes (Lamm, 1997).

We have also detected another QTL at 25.2 on BTA6 significantly associated with the SNP ss61565956. An interesting candidate gene in this region is DAPP1, also known as Bam32, which is expressed in B cell lymphocytes and has been implicated in B cell antigen receptor (BCR) signaling. Thus, antigen binding to BCR involves a chain of signaling processes that are critical for B cell-fate decisions such as proliferation and differentiation, and BCR-mediated antigen internalization, processing, and presentation to T cells (Pierce, 2002). Studies of Bam32 deficient mice have shown that Bam32 mediates BCR-induced proliferation of B cell but not survival (Han et al., 2003), it regulates B cell antigen receptor internalization (Niironen et al., 2004), and it promotes the formation of stable interactions between B cells and T cells needed for efficient T cell activation, most likely by promoting adhesion to integrin ligands expressed on T cells (Al-Alwan et al., 2010).

We also found suggestive evidence for a QTL affecting CM at 75.9 Mb on BTA9.

We observed a suggestive evidence for a QTL affecting CM at 69.2 Mb on BTA11. Also, a suggestive QTL for CM was observed in our analysis at 30.4 Mb.

On BTA13, we detected a genome-wide significant QTL for CM, CM11 and CM12 at 57.7 Mb on BTA13. There were two closely located SNPs, which showed genome-wide association, located very close to the endothelin 3 gene [http://www.ensembl.org/Bos_taurus/]. The endothelins ET-1, ET-2, and ET-3 constitute a family of 21-amino acid peptides that are produced by numerous cells and tissues such as macrophages, and endothelial and epithelial cells (Giaid et al., 1991). In addition to a vasoconstrictive effect, they also have an impact on many different cell types, including activation of neutrophils (Elferink and De Koster, 1998). Neutrophils are blood-borne leukocytes that combat bacterial and fungal infections by phagocytosis or release of antimicrobial peptides (Selsted and Ouellette, 2005). Another possible candidate gene located in this region is Phactr3 (phosphatase and actin regulator 3), which has been shown to stimulate cell spreading and migration through direct interaction with the actin cytoskeleton (Sagara et al., 2009). Cell mobility is critically important for cell-mediated immune response (Luster et al., 2005). Lund et al. (2008) detected QTL for SCS between microsatellite markers BM9248 (29.1 cM) and BL1071 (68.6 cM; 71.9 Mb on Btau_4.0). The QTL interval reported was very large (39.5 cM) in the linkage analysis. In contrast, the present GWAS was able to narrow the QTL to a 4 Mb region.

We have identified a genome-wide significant QTL at 37.7 Mb on BTA20. The most significant SNP, rs41940571 is linked to the gene RIPTOR independent companion of MTOR, complex 2. There are several other genes located in this QTL region in the Btau_4.0 assembly. Among these is the C9 gene, encoding the complement component C9 precursor. The complement system is part of the immune response against invading pathogens. Activation of the complement system through the classical, alternative, or mannan-binding lectin pathways ultimately leads to formation of the Membrane Attack Complex, which creates pores in bacterial membranes, resulting in cell lysis. Complement C9 is the pore-forming subunit of MAC and mutations in this gene are associated with increased risk of infections, for example meningococcal meningitis (Kira et al., 1998; Zoppi et al., 1990; Horiuchi et al., 1998). Lund et al. (2008) observed a QTL for UD between 31.3 and 48.2 Mb on BTA20. These two studies point probably to the same QTL.

On BTA23, Lund et al. (2008) observed a QTL for SCS between BMS466 (46.1 cM; 43.4 Mb on Btau_4.0) and INRA090 (53.2 cM) and a QTL for UD between 43.9-46.6 Mb. Ashwell et al. (1997) and Heyen et al. (1999) detected QTL for SCS on BTA3 at 39.9 and 48.6 Mb, respectively. Our study found suggestive evidence for a QTL affecting CM and SCS on this chromosome at 11.7 Mb, far away from the earlier reports. The QTL we found could be a different one than those reported earlier.

We also detected a genome-wide significant QTL affecting CM and CM2 at the proximal end of BTA14 (0.7 Mb) which was not detected in the same population by Lund et al. (2008). Three SNPs showed genome-wide significant association with MAS2. A region around 1.3 Mb with CYP11B1 harbors a QTL for SCS in German Holstein cattle (Kaupe et al. 2007) which could be the same QTL as detected in the present study. There are several genes located in the QTL region in Btau_4.0 including DGAT1 (Grisart et al. 2002) which has a large influence on phenotypic variance in milk fat content and other milk characteristics.

The genetic correlation between clinical mastitis and SCS is >0.70 (Lund et al. 1999, Carlen et al. 2004; Heringstad et al. 2006). Therefore, it was expected that many of the QTL affecting CM would also affect SCS. Out of nine significant QTL affecting clinical mastitis traits, five showed effect on SCS. This was as expected due to high genetic correlation between clinical mastitis and SCS. As we are analyzing both clinical mastitis and SCS in the present study, may help to indicate the extent of SCS QTL from the literature can be expected to affect clinical mastitis. Out of the six mastitis traits analyzed in the present study, maximum number of QTL was observed for mastitis index which was an index combining clinical mastitis from first three lactations.

The present study identified several mastitis QTLs. We used association study with dense SNP markers in a mixed model analyses which was observed to perform best for samples from complex pedigreed population like cattle (Sahana et al. 2010b). In the present study QTL positions were refined to much narrower genomic regions than has been possible by previous linkage analysis. This association mapping identified SNPs which are in linkage disequilibrium with the QTL, or which are causative mutations, and therefore, marker-based selection at the population level for mastitis resistance could be carried out. Some of the QTL regions were narrow enough to initiate further search for candidate genes underlying mastitis QTL.

Example 2

Ultra-fine-mapping of clinical mastitis and somatic cell score QTL in dairy cattle

Clinical mastitis and somatic cell score QTL in dairy cattle were fine-mapped using high-density SNP Chips comprising 777,962 SNP probes.

Association mapping

Association mapping identifies specific functional variants (i.e., loci, alleles) linked to phenotypic differences in a trait, to facilitate detection of trait causing DNA sequence polymorphisms and/or selection of genotypes that closely resemble the phenotype. Association mapping has been variously defined (Chakraborty and Weiss 1988; Kruglyak 1999), and has also been referred to as “association genetics,” “association studies,” and “linkage disequilibrium mapping”. Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and risk of disease or quantitative traits. Recent advances in our understanding of genetic variation and the technology to measure such variation have made GWAS feasible.

In the present example, association mapping has been used to identify single nucleotide polymorphisms (SNPs) which are associated with mastitis resistance in dairy cattle. Several Quantitative Trait Loci (QTL) were identified which can be usefully applied in selection of animals for improvement of resistance to mastitis.

Phenotypes

The genome scan for mastitis resistance was carried out using Danish and Swedish Holstein cattle for nine mastitis phenotypes analysed. The phenotype used for mapping quantitative trait loci (QTL) for mastitis resistance was udder health index estimated for Nordic cattle genetic evaluation (NAV, Pedersen, 2008, www.nordicebv.info). The udder health traits currently evaluated in NAV included four clinical mastitis traits from three lactations, all measured as a binary trait (Table 5). These four mastitis traits are weighted together to form a mastitis resistance index (CM), standardized to a mean of 100 and a standard deviation of 10 (Johansson et al. 2007). There were 4200 progeny tested bulls from Danish, Swedish and Finnish Holstein dairy cattle with recode for these nine mastitis related phenotypes. The SNP genotype and phenotypes of these bulls were utilized for association mapping.

Table 5. Abbreviations and definitions of traits included in the study

Trait No.	Trait abbreviation	Trait definitions
1	CM11	Clinical mastitis (1) or not (0) between -15 and 50

		days after 1st calving
2	CM12	Clinical mastitis (1) or not (0) between 51 and 305 days after 1st calving
3	CM2	Clinical mastitis (1) or not (0) between -15 and 305 days after 2nd calving
4	CM3	Clinical mastitis (1) or not (0) between -15 and 305 days after 3rd calving
5	CM	Clinical mastitis: $0.25*CM11 + 0.25*CM12 + 0.3*CM2 + 0.2*CM3$
6	SCC1	Log. somatic cell count average in 1st lactation
7	SCC2	Log. somatic cell count average in 2nd lactation
8	SCC3	Log. somatic cell count average in 3rd lactation
9	SCC	Log somatic cell count: $0.5*SCC1 + 0.3*SCC2 + 0.2*SCC3$

Genotypes

The Holstein bulls were genotyped using the Illumina Bovine SNP50 BeadChip. Genotyping was done by the Illumina Bovine SNP50 BeadChip (Illumina Inc., http://www.illumina.com/Documents/products/datasheets/datasheet_bovine_snp50.pdf) at the Danish Institute of Agricultural Sciences, Research Center Foulum, Department of Molecular Biology and Genetics and at GenoScan, AgroBusiness Park Foulum. The platform used was an Illumina® Infinium II Multisample assay device. SNP chips were scanned using iScan and analyzed using Beadstudio ver. 3.1 software. The quality parameters used for selection of SNPs were minimum call rates of 85% for individuals and of 95% for loci. Marker loci with minor allele frequencies (MAFs) below 5% were excluded. The minimal acceptable GC score was 0.60 for individual typings. Individuals with average GC scores below 0.65 were excluded. The number of SNPs after quality control was 43,415 in the 50k dataset. A total of 557 Holstein bulls in the EuroGenomics project (Lund et al., 2011) were re-genotyped using the BovineHD Genotyping BeadChip (http://www.illumina.com/Documents/products/datasheets/datasheet_bovineHD.pdf). There are a total of 777,962 SNPs on the BovineHD BeadChip that uniformly span over entire bovine genome with an average gap size of 3.43 kb and a median gap size of 2.68 kb. The quality control parameters set for HD data were similar as it was for 50K chip as described above. The 50k genotypes were imputed to

the HD genotypes using Beagle software package (Browning and Browning, 2009), based on the marker data of the HD genotyped bulls (Su et al 2011; interbull meeting presentation). The markers in the 50k chip but not included in the HD chip were excluded in the imputation process. The number of SNPs after imputation to BovineHD chip was 648,219. The genome positions of the SNPs were taken from UMD3.1 assembly (http://www.ensembl.org/Bos_taurus/2011_09_cow_genebuild.pdf). The physical maps for the 648,219 SNPs located on 29 Bovine autosomes are available at www.illumina.com.

The model used for association mapping

The details of the association mapping model are described by Yu et al. (2006) and Sahana et al. (2010). The statistical model used for association analyses was:

$$y_i = \mu + bx_i + s_i + e_i$$

Where y_i was the single trait estimated breeding value of individual i , μ was the general mean, x_i was a count in individual i of one of the two alleles (with an arbitrary labeling), b was the allele substitution effect, s_i was the random effect of the sire of individual i , assumed to have a normal distribution $N(0, A\sigma_s^2)$, where A is the additive relationship matrix and σ_s^2 is the sire variance, and e_i was a random residual of individual i assumed to follow a normal distribution with mean zero and error variance, σ_e^2 . Testing was done using a Wald test against a null hypothesis of $H_0: b = 0$. The significance threshold was determined using a Bonferroni correction. The genome-wide significance threshold was calculated by dividing the nominal significance threshold of 0.05 by the total numbers of SNPs included in the analysis.

Results

A total 61 QTL regions on 22 chromosomes associated with mastitis related traits were identified. The QTL regions along with the highest significantly associated SNP for each QTL are presented in Table 6; cf. figure 17. The data sheet for the BovineHD Genotyping BeadChip can be downloaded from: (http://www.illumina.com/Documents/products/datasheets/datasheet_bovineHD.pdf). The names and positions of the SNPs are available the website of Illumina, cf. www.illumina.com.

Table 6: cf. figure 17

Table 7:

Column number	Column headings	Description
---------------	-----------------	-------------

1	Region No.	Serial number for the QTL regions
2	Chr	Chromosome number
3	Start-SNP	The genome-wide significant SNP number at the beginning of the QTL region
4	Start Pos.	Position of the 'Start-SNP' on the chromosome (Bp)
5	End-SNP	The genome-wide significant SNP number at the end of the QTL region
6	End Pos.	Position of the 'End-SNP' on the chromosome (Bp)
7	Region-BP	The QTL region in Bp
8	No. of sig. SNP	Number of genome-wide significant SNP within the QTL region
9	Most sig. SNP name	The highest significant SNP within a QTL region
10	Top SNP Pos	The highest significant SNP's position on the chromosome in Bp
11	$-\log_{10}(\text{p-value})$	$-\log_{10}(\text{p-value})$ for the highest significant SNP in the QTL region.
12	Traits showing association	1-CM11, 2-CM12, 3-CM2, 4-CM3, 5-CM, 6-SCC1, 7-SCC2, 8-SCC3, 9-SCC. The descriptions of the traits are given in the text.

Example 3

Targeted genome-wide association for causative mutation using whole genome sequence data for a QTL region on BTA6 (88-96 Mb).

Targeted Region (TR).

The genomic region from 88-96 Mb on BTA6 was selected for targeted genome-wide association study with SNP variants identified from the whole genome sequence of 90 bulls. This genomic region was selected as it showed the strongest association with clinical mastitis in analyses of the Illumina Bovine SNP50 BeadChip (HD SNP chip). The most significant SNP association with clinical mastitis for HD SNP chip analyses was BovineHD0600024355 located at 88,919,352 Bp on BTA6.

Whole Genome Sequence (WGS).

The whole genome of ninety bulls from three breeds (~30 each from Nordic Holstein, Danish Jersey and Nordic Red breed) was sequenced (~10X coverage) at Beijing Genomic Institute (BGI), China. The whole genome sequences were analyzed and more than 24 million variants were observed. The variants were functionally annotated. The SNP polymorphisms for the targeted region (TR) on BTA6 harbouring mastitis QTL were extracted. There were a total of 41,993 SNP variants within the TR of 8

Mb. There were 5,193 Nordic Holstein bulls with the clinical mastitis phenotypes and the HD SNP chip genotypes. These animals were imputed for the 41,993 SNP variants identified in WGS using software Beagle (Browning and Browning, 2007). The association analyses were carried out for these 5,193 bulls' data using the mixed linear model analysis (Yu et al. 2006). The results showed an association with clinical mastitis of the neuropeptide FF receptor 2 (NPFFR2) gene (Figure 16). The gene is located at 89,052,210 – 89,059,348 Bp on BTA6. A non-synonymous mutation within NPFFR2 gene, identified by SNP chr6_89059253, located at 89,059,253 Bp on BTA6 had the $-\log_{10}(p\text{-value}) = 37.4$. This SNP variant is associated with clinical mastitis in the first lactation (CM11). Thus, the NPFFR2 gene appears to strongly affect clinical mastitis and the chr6_89059253 SNP is likely the causative mutation affecting resistance to clinical mastitis in Nordic Holstein cattle or this SNP is in strong linkage disequilibrium with causative polymorphism responsible for resistance to clinical mastitis.

Example 4

Targeted region-wise association studies (RWAS)).

Genome-wide association studies (GWAS) was carried out previously for nine mastitis traits in Nordic Holstein cattle. The genotyping was done using Bovine HD SNP chip. A linear mixed model analyses was carried out to identify the SNPs significantly associated with mastitis resistance. Based on this GWAS study, six genomic regions were selected for targeted GWAS with whole genome sequence data (Table 8).

Whole genome sequencing

A total of 90 bulls' (~30 of each of Danish Red, Danish Jersey and Nordic Holstein) whole genomes were sequenced at BGI, China. The sequence data was analyzed at by the Quantitative Genetics and Genomic Centre (QGG), MBG, Aarhus University. The average genome coverage was more than 10X. Alignment of sequence reads to the cattle reference genome was done and the candidate sites or regions at which one or more samples differ from the reference sequence were identified. The quality control measures removed candidate sites that likely were false positives. The variants calls i.e. the estimation of the alleles present in each individual at variant sites was carried out using VCF tools (<http://vcftools.sourceforge.net/>). A total of more than 24 millions DNA level variants (single nucleotide polymorphism (SNP), insertion-deletions (indel), copy number variation (CNV) etc.) observed

across three cattle breeds. All the variants were functionally annotated for search of candidate polymorphisms affecting mastitis related traits.

Targeted Imputation

Six chromosomal regions (Table 8) were selected based on GWAS study with HD SNP chip on nine mastitis resistance traits in Nordic Holstein cattle. The length of the regions and the number of SNP variants (from whole genome sequence data) for each region selected after quality control are given in Table 8. The phenotypes (estimated breeding values) were available for 5193 Nordic Holstein bulls for nine mastitis related traits. The SNP chip genotypes (50k and 777k) of these bulls were imputed to the sequence level for the targeted regions using the software Beagle (Browning and Browning, 2006). All the SNP position mentioned here is as per the Bovine genome assembly (UMD3.1).

Table 8. The selected targeted regions on six chromosomes for RWAS. The highest significant SNP across nine mastitis traits analyzed for each targeted region is also presented in the table.

Chromosome	Region (Mb)	No. of SNPs	Trait with lowest p-value	SNP	Position (Bp)	MAF	$-\log_{10}(\text{p-value})$
BTA5	84-95	55,046	CM11	Chr5_92753829	92,753,829	0.204	9.89
BTA6	88-96	41,993	CM11	Chr6_88977023	88,977,023	0.432	38.76
BTA13	57-63	18,935	CM	Chr13_57608628	57,608,628	0.305	15.07
BTA16	48-55	27,709	CM11	Chr16_50529178	50,529,178	0.019	14.51
BTA19	55-58	16,145	SCS3	Chr19_55296191	55,296,191	0.380	10.90
BTA20	32-40	30,025	CM2	Chr20_35965955	35,965,955	0.203	15.24

Region-wise association studies (RWAS)

A SNP-by-SNP analysis where each SNP was fitted separately in a linear mixed model (**LMM**) following Yu et al. (2006). Complex familial relationship is the primary confounding factor in GWAS study in livestock population. LMM which include the relationship among individuals through a polygenic effect is able to control the false positives due to family structure (Yu et al., 2006).

Linear Mixed Model

For each SNP separately, the association between the SNP and the phenotype was assessed by a single-locus regression analysis using a linear mixed model. The model was as follows:

$$y = 1\mu + mg + Zu + e$$

where $\mathbf{y}$ is the vector phenotypes (EBV), $\mathbf{1}$ is a vector of 1s with length equal to number of observations, μ is the general mean, $\mathbf{m}$ is the genotypic score (obtained from Beagle output; values ranged between 0 and 2) associating records to the marker effect, g is a scalar of the associated additive effect of the SNP, $\mathbf{Z}$ is an incidence matrix relating phenotypes to the corresponding random polygenic effect, $\mathbf{u}$ is a vector of the random polygenic effect with the normal distribution $N(\mathbf{0}, \mathbf{A}\sigma_u^2)$, where $\mathbf{A}$ is the additive relationship matrix and σ_u^2 is the polygenic variance, and $\mathbf{e}$ is a vector of random environmental deviates with the normal distribution $N(0, \sigma_e^2)$, where σ_e^2 is the error variance. The model was fitted by restricted maximum likelihood (REML) using the software DMU (Madsen and Jensen, 2011) and testing was done using a Wald test against a null hypothesis of $g=0$.

Significant Associations

A SNP was considered to have significant association if the p-value crossed the region-wise significant threshold after Bonferroni correction for multiple testing.

Association analyses with the most important SNP as cofactor in the model

A large number of SNPs crossed region-wide significant threshold. As the LD is expected to be high these significant effect of the SNPs could be due to linkage to only one casual variant segregating in the targeted region. However, as the regions were quite large (>5Mb in some cases), it is also possible that the effect observed was due to multiple causative variants segregating in Nordic Holstein population. This analysis was done to see if any SNP shows significant association after the most important SNP from the LMM analyses and/or functional annotation was included in the model as cofactor (Table 9). The analysis was done using *lme* function of *nlme* of R-package (<http://cran.r-project.org/>). The model was as below.

$$Y_{ij} = \mu + S_i + \text{fixSNP} + \text{SNP}_m + e_{ij}$$

where Y_{ij} is the residual phenotype obtained from an animal model (i.e. adjusted for the pedigree) for the j th animal of i th sire, S_i is the random effect of the i^{th} sire, fixSNP is the regression of genotype score for the highest significant SNP from the LMM (or the most important SNP based on functional annotation among a few top ones), SNP_m is the regression of the genotype score of the m^{th} SNP ($m \neq \text{fixSNP}$) and e_{ij} is the random error.

Table 9. The SNP selected based on the strength of association and also functional annotation to be used as cofactor the linear model.

Chromo- some	Region (Mb)	SNP used as cofactor	SNP Position (Bp)	MAF
BTA5	84-95	Chr5_9275382 9	92,753,829	0.204
BTA6	88-96	Chr6_8905925 3	89,059,253	0.483
BTA13	57-63	Chr13_57572723	57,572,723	0.137
BTA16	48-55	Chr16_50529178	50,529,178	0.019
BTA19	55-58	Chr19_55296191	55,296,191	0.380
BTA20	32-40	Chr20_35965955	35,965,955	0.203

Results

The manhattan plots for the RWAS (both linear mixed model, and the linear model with the most important SNP as cofactor) are presented in figures 18-23. The lists of the most significant SNP associated with nine mastitis traits in Nordic Holstein cattle for each of these genomic regions selected for targeted GWAS are presented in the tables below. The candidate polymorphisms of the each of the targeted regions were searched based on the functional annotation information and examined for their association strengths.

All the six targeted regions had wide picks of association. However, including the most significant associated SNP as cofactor (Table 9), the entire range of associated region collapses. This indicates the SNPs mentioned in Table 9 which were used as cofactor are either the real causal polymorphisms affecting mastitis resistance in Nordic Holstein or are in very high LD with the real causal polymorphism in the targeted regions. Therefore, these SNPs could be used as predictor of mastitis resistance on individual animals in Holstein cattle. Results from individual genomic regions are discussed in details below.

BTA5 (84-95 Mb)

The most significant SNP for each of the nine mastitis related traits are presented in table 10 for the targeted region on BTA5. The total length of the targeted region on BTA5 was 9 Mb and there were two regions (at 86.99 and 92.75 Mb) where the highly significant SNPs were concentrated. The man-hatton plot for this region is presented in figure 18.

Table 10. The most significant SNP association for nine mastitis traits in the targeted region on BTA5

Trait	SNP name	SNP po- sition (Bp)	MAF	b- value	SE	- log ₁₀ (p- value)	Genotype	Allele increasing mastitis resistance
CM11	Chr5_92753829	92753829	0.204	2.042	0.317	9.89	A/G	G
CM12	BovineHD0500024659	86998734	0.487	-1.135	0.201	7.80	G/A	G
CM2	Chr5_87360522	87360522	0.222	14.056	2.582	7.26	A/T	T
CM3	BovineHD0500026657	93941017	0.254	-1.224	0.223	7.40	A/G	A
CM	Chr5_92753829	92753829	0.204	1.869	0.313	8.61	A/G	G
SCS1	Chr5_87360522	87360522	0.222	11.068	2.593	4.70	A/T	T
SCS2	Chr5_94040670	94040670	0.160	-1.577	0.378	4.51	C/A	C
SCS3	Chr5_89528205	89528205	0.020	13.344	2.947	5.22	G/T	T
SCS	Chr5_87360522	87360522	0.222	10.758	2.556	4.58	A/T	T

Candidate polymorphism within the BTA5 targeted region:

BTA5 (86.99 Mb): There is a huge intron at 86.99 Mb. Upstream there is a non-synonymous polymorphism (allele frequency of the alternative allele for the polymorphisms (alt) 64%) at 86,948,388 which

could be the candidate polymorphism. Downstream at 87,004,771 (alt 15%) and 87,004,957 (alt 3%), there are two polymorphisms in a non-coding gene in an intron. Further downstream there is a synonymous coding splice-site polymorphism at 87,023,448 (alt 31%).

BTA5 (92.75 Mb): The gene around 92,496,500 has three polymorphisms at 92,496,251 (alt 54%), 92,496,510 (alt 28%) and 92,496,586 (alt 3%). Downstream the next annotation starts around 93,688,996 (gene ENSBTAG00000013541). However, all polymorphisms in this gene are either intronic, upstream or downstream. The next downstream a candidate causative polymorphism could be at 93,939,231 (alt 7%) (gene ENSBTAG00000008541) which is non-synonymous coding. However, none of above candidate polymorphisms discussed within the targeted region of BTA5 showed strong association signal across the mastitis traits analyzed.

BTA5: Genes associated with mastitis according to the analysis are summarized in the table below. For clinical mastitis the top SNPs are concentrated around 92.7 Mb, whereas there are minor peaks at positions 87 Mb, (88.8 Mb, 90.9 MB) and 93.4 Mb. The following genes are located in the two major peak regions around 87Mb and 92.7Mb.

Table 11. BTA5: Genes associated with mastitis according to the present analysis.

Ensembl Gene ID	Common gene name	Associated gene name	Gene location (UMD3.1)
ENSBTAG00000022360	Transcription factor SOX-5	SOX5	86,571,273-87,036,285
ENSBTAG00000005833	Ethanolamine kinase 1	ETNK1	87,967,760-88,017,062
ENSBTAG00000001673	Hypothetical protein LOC520387	LOC520387	88,099,588-88,191,001
ENSBTAG00000013202	1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase zeta-1	PLCZ1	91,771,436-91,820,146
ENSBTAG00000047048	Novel_gene		91,880,701-91,882,214
ENSBTAG00000046178	Noncoding		91,945,426-91,946,169
ENSBTAG00000020715	Phosphoinositide-3-kinase, class 2, gamma polypeptide	PIK3C2G	91,835,146-92,276,939

ENSBTAG00000030493	Ras-related and estrogen-regulated growth inhibitor-like protein	RERGL	92,432,331-92,442,968
ENSBTAG00000013541	LIM domain only protein 3	LMO3	93,693,961-93,757,644
ENSBTAG00000008541	Microsomal glutathione S-transferase 1	MGST1	93,926,791-93,950,162
ENSBTAG00000009444	Solute carrier family 15, member 5	SLC15A5	94,030,765-94,127,585

Among the candidate genes in this region we find RERGL encoding Ras-related and estrogen-regulated growth inhibitor-like protein. There is little or no functional information about this specific gene in the literature. However, the Ras family of small GTPases is a group of more than 150 proteins that function in diverse biological processes including immunity and inflammation (Johnson and Chen, Current Opinion in Pharmacology 12, 458-463, 2012). Another good candidate gene which might be relevant in relation to mastitis is PIK3C2G, which codes for phosphoinositide-3-kinase class 2 gamma subunit. Many PI3K enzymes play an important role in the functioning of immune cells (Johnson and Chen, Current Opinion in Pharmacology, 2012; Koyasu, Immunology, 2003).

BTA6 (88-96 Mb)

The most significant SNP for each of the nine mastitis related traits are presented in table 12 for the targeted region of BTA6. The targeted region on BTA6 was 8 Mb in length. The manhattan plot for this region is presented in the figure 19.

Table 12. The most significant SNP association for nine mastitis traits in the targeted region on BTA6.

Trait	SNP name	SNP position (Bp)	MAF	b-value	SE	$-\log_{10}(p\text{-value})$	Genotype	Allele increasing mastitis resistance
CM11	Chr6_88977023	88977023	0.432	-2.800	0.211	38.76	C/T	C
CM12	Chr6_88612186	88612186	0.403	-2.772	0.262	25.27	G/T	G
CM2	Chr6_88610743	88610743	0.169	-5.945	0.578	23.84	T/A	T
CM3	Chr6_88977023	88977023	0.432	-2.447	0.210	30.21	C/T	C

CM	Chr6_88977023	88977023	0.432	-2.493	0.209	31.66	C/T	C
SCS1	Chr6_88326504	88326504	0.124	-6.134	0.124	19.45	G/A	G
SCS2	Chr6_88326504	88326504	0.124	-5.756	0.697	15.75	G/A	G
SCS3	Chr6_88326504	88326504	0.124	-5.738	0.734	14.19	G/A	G
SCS	Chr6_88326504	88326504	0.124	-5.886	0.659	18.25	G/A	G

Candidate polymorphism for the BTA6 targeted region:

SNP, Chr6_89059253, is a strong candidate polymorphism (alt 48%, gene ENSBTAG00000009070) for the targeted region of BTA6. This SNP showed very strong association with all the five clinical mastitis traits (CM11, CM12, CM2, CM3 and CM) (Table 13).

Table 13. The most associated polymorphism SNP from annotation were located at 89,059,253 on BTA6. This SNP show high association with all the five clinical mastitis traits.

SNP-name	SNP position (BP)	trait	MAF	$-\log_{10}(\text{p-value})$	Genotype	Allele increasing mastitis resistance
Chr6_89059253	89059253	CM11	0.483	37.40	G/A	G
Chr6_89059253	89059253	CM12	0.483	21.68	G/A	G
Chr6_89059253	89059253	CM2	0.483	22.08	G/A	G
Chr6_89059253	89059253	CM3	0.483	29.34	G/A	G
Chr6_89059253	89059253	CM	0.483	30.62	G/A	G
Chr6_89059253	89059253	SCS1	0.483	7.39	G/A	G
Chr6_89059253	89059253	SCS2	0.483	7.56	G/A	G
Chr6_89059253	89059253	SCS3	0.483	7.21	G/A	G
Chr6_89059253	89059253	SCS	0.483	8.30	G/A	G

Table 14. BTA6: Genes associated with mastitis according to the present analysis.

For clinical mastitis the top SNPs are concentrated around 88.9 Mb, whereas the major peak for SCS is centered on 88.4 MB. Here we find the following genes:

Ensembl Gene ID	Description	Associated gene name	Gene location (UMD3.1)
ENSBTAG00000018531	Immunoglobulin J chain	IGJ	87,759,438-87,768,834
ENSBTAG00000009310	UTP3, small subunit (SSU) processome component, homolog (<i>S. cerevisiae</i>)	UTP3	87,798,136-87,799,560
ENSBTAG00000016795	RUN and FYVE domain containing 3	RUFY3	87,819,398-87,910,688
ENSBTAG00000008577	G-rich sequence factor 1	GRSF1	87,922,395-87,941,062
ENSBTAG00000016290	MOB kinase activator 1B	MOB1B	87,976,520-88,030,195
ENSBTAG00000012397	Deoxycytidine kinase	DCK	88,049,498-88,077,488
ENSBTAG00000002348	Electrogenic sodium bicarbonate cotransporter 1	SLC4A4	88,182,303-88,541,046
ENSBTAG00000013718	Vitamin D-binding protein precursor	GC	88,695,940-88,739,180
ENSBTAG00000009070	Neuropeptide FF receptor 2	NPFFR2	89,052,210-89,059,348
ENSBTAG00000006507	ADAM metallopeptidase with thrombospondin type 1 motif, 3	ADAMTS3	89,162,542-89,460,195

One associated gene is the **IGJ** gene, which encodes the immunoglobulin J polypeptide although it should be noted that the gene might be located too far away from the peak. This protein interacts with immunoglobulins IgM and IgA. IgM is the first antibody produced in the primary immune response to microbial infections whereas IgA is engaged in the defense against microorganisms in particular those invading the host through mucosal surfaces. Another associated gene is Deoxycytidine kinase (**DCK** gene), which catalyzes the rate-determining step in the deoxyribonucleoside salvage pathway. DCK is expressed in thymus and bone marrow, possibly indicating a role in lymphopoiesis. Mice lacking DCK enzyme activity revealed a combined immune deficiency phenotype, i.e. they produce very low levels of both T and B lymphocytes (Toy et al., PNAS, 2010). A relevant gene in this region is the GC gene, which belongs to the albumin family. The **GC** protein binds vitamin D and is involved in (inflammation-primed) activation of macrophages (Yamamoto and Naraparaju, Journal of Immunology, 1996; Kisker et al., Neoplasia, 2003). Another gene associated with mastitis in this region is the NPFFR2 gene (also known as GPR74), which encodes neuropeptide FF receptor 2. NPFFR2 show expression in sev-

eral tissues including thymus, liver, spleen, brain, spinal cord and other. NPFF receptors have been implicated in hormonal modulation, regulation of food intake, thermoregulation and nociception through modulation of the opioid system (information from GeneCards). However, it is well documented that many neuropeptides participate in immune responses for example by acting as stimulators or inhibitors of macrophage activity (reviewed by Ganea and Delgado, *Microbes and Infection*, 2001). NPFFR2 also binds the prolactin-releasing-hormone, suggesting that NPFFR2 may play a role in prolactin secretion (Ma et al., *European journal of neuroscience*, 2009). Interestingly, in addition to regulating lactation, prolactin also acts as an important regulator of the immune system (Yu-lee, *Recent Progress in Hormone Research*, 2002).

BTA13 (57-63 Mb)

The most significant SNP for each of the nine mastitis related traits for the targeted region of BTA13 are presented in table 15. The targeted region was 6 Mb in length. The manhattan plot for this region is presented in the figure 20.

Table 15. The most significant SNP association for nine mastitis traits in the targeted region on BTA13

Trait	Top-SNP	Position (Bp)	MAF	b-value	SE	$-\log_{10}(\text{p-value})$	Genotype	Allele increasing mastitis resistance
CM11	Chr13_57608336	57608336	0.072	-8.127	1.029	14.46	A/C	A
CM12	Chr13_57608354	57608354	0.294	-1.793	0.251	12.00	A/G	A
CM2	Chr13_59584651	59584651	0.234	-6.433	0.899	12.02	T/G	T
CM3	Chr13_59584651	59584651	0.234	-6.728	0.857	14.32	T/G	T
CM	Chr13_57608628	57608628	0.305	-1.908	0.236	15.07	A/G	A
SCS1	Chr13_57608354	57608354	0.294	-1.619	0.259	9.35	A/G	A
SCS2	Chr13_60621602	60621602	0.014	-29.835	4.511	10.39	A/G	A
SCS3	Chr13_60621602	60621602	0.014	-31.429	4.678	10.69	A/G	A
SCS	Chr13_60621602	60621602	0.014	-28.314	4.290	10.34	A/G	A

Candidate polymorphism for BTA13 targeted region:

Two possible candidate polymorphisms based on functional annotation within the targeted region of BTA13 could be two consecutive SNPs located at 57579568 and 57579569 and both of them showed very high associations with mastitis traits.

Table 16. Association results for the two most associated polymorphism SNPs from annotation with clinical mastitis on BTA13.

SNP-name	SNP position (BP)	trait	MAF	$-\log_{10}(\text{p-value})$	Genotype	Allele in- creasing mastitis resistance
Chr13_57579568	57579568	CM11	0.094	13.22	G/T	T
Chr13_57579568	57579568	CM12	0.094	9.19	G/T	T
Chr13_57579568	57579568	CM2	0.094	8.23	G/T	T
Chr13_57579568	57579568	CM3	0.094	12.11	G/T	T
Chr13_57579568	57579568	CM	0.094	12.59	G/T	T
Chr13_57579568	57579568	SCS1	0.094	8.22	G/T	T
Chr13_57579568	57579568	SCS2	0.094	5.80	G/T	T
Chr13_57579568	57579568	SCS3	0.094	5.62	G/T	T
Chr13_57579568	57579568	SCS	0.094	7.71	G/T	T
Chr13_57579569	57579569	CM11	0.063	13.22	C/G	G
Chr13_57579569	57579569	CM12	0.063	9.20	C/G	G
Chr13_57579569	57579569	CM2	0.063	8.23	C/G	G
Chr13_57579569	57579569	CM3	0.063	12.11	C/G	G
Chr13_57579569	57579569	CM	0.063	12.60	C/G	G
Chr13_57579569	57579569	SCS1	0.063	8.22	C/G	G
Chr13_57579569	57579569	SCS2	0.063	5.80	C/G	G
Chr13_57579569	57579569	SCS3	0.063	5.62	C/G	G
Chr13_57579569	57579569	SCS	0.063	7.71	C/G	G

Table 17. BTA13. Genes associated with mastitis according to the present analysis.

Ensembl Gene ID	Location	Gene name	Short name	Comments
ENSBTAG00000020261	57056797-57091107	Cadherin 26	CAD26	Cadherins are a family of adhesion molecules that mediate Ca ²⁺ -dependent cell-cell adhesion in all solid tissues and modulate a wide variety of processes, including cell polarization and migration.
ENSBTAG00000012109	57571799-57596875	Endothelin 3	EDN3	Endothelins are proteins that constrict blood vessels and raise blood pressure. endothelium family member Edn3, acting through the endothelin receptor EdnrA. This might mediate transport of energy and other small molecules to specific tissues.
ENSBTAG00000018053	58537701-58585721	Ras-related protein Rab-22A	RAB22A	The protein encoded by this gene is a member of the RAB family of small GTPases. The GTP-bound form of the encoded protein has been shown to interact with early-endosomal antigen 1, and may be involved in the trafficking of and interaction between endosomal compartments. Small GTPases of the RAB family, such as RAB22A, are involved in the transport of macromolecules along endocytic and exocytic pathways.
	59.1 Mb	novel, 3 transcripts		blastp hit to "predicted: z-DNA binding protein 1 (Bos taurus)" and "DNA-dependent activator of IFN-regulatory factor (Sus scrofa)". Could be interesting if involved in interferon regulation.
	60.2 Mb	novel protein		Domains Ig-like. Having Ig-like domains

		coding		could indicate involvement in recognition of other molecules.
ENSBTAG00000018418	60487257-60492005	Transmembrane protein 74B	TMEM74B	TMEM74 is a lysosome and autophagosome protein that plays a role in autophagy, however as human TMEM74 is located on Hsa8 it is not the homologue of this TMEM74B gene.
ENSBTAG00000013330	61123467-61142447	TBC1 domain family member 20	TBC1D20	<u>Sklan et al. (2007) showed that reduction of TBC1D20 expression by siRNA severely impaired Hepatitis C Virus replication and inhibited new infection. However, as this is a virus it might be a different pathway and not relevant for mastitis.</u>
ENSBTAG00000048288	61314568-61316738	Defensin, beta 129	DEFB129	The beta defensins are antimicrobial peptides implicated in the resistance of epithelial surfaces to microbial colonization.
ENSBTAG00000003364	61523659-61533444	Beta-defensin 119	DEFB119	
ENSBTAG00000048009	61501526-61501651	defensin, beta 117	DEFB117	
ENSBTAG00000027384	61562053-61566096	beta-defensin 122a	DEFB122a	
ENSBTAG00000027383	61572838-61577455	beta-defensin 122	DEFB122	
ENSBTAG00000020555	61584391-61595672	beta-defensin 123	DEFB123	
ENSBTAG00000031254	61612683-61615456	beta-defensin 124	DEFB124	
ENSBTAG00000016169	61726125-61727283	DNA-binding protein inhibitor ID-1	ID1	During B-cell differentiation, Id inhibitory proteins, particularly ID1 and ID2, are expressed at high levels in pro-B cells

				(Sun et al., 1991; Wilson et al., 1991) and are downregulated as cells differentiate into pre-B and mature B cells, presumably for the purpose of releasing the bHLH proteins (e.g., E2A; 147141) that are important for differentiation.
	61.9 Mb	Uncharacterized protein		Blast shows similarity to "interferon regulatory factor 4", which is a transcription factor essential for the development of T helper-2 (Th2) cells, IL17-producing Th17 cells, and IL9-producing Th9 cells (Staudt et al., 2010).
ENSBTAG00000016348	62030345-62054881	XK, Kell blood group complex subunit-related family, member 7	XKR7	Blood groups are interesting as they often presents a defense against macromolecules. The exact function of the Kell blood groups has not been deduced.
ENSBTAG00000019200	62850752-62869092	BPI fold containing family B, member 2	BPIFB2	BPIL1 shares significant similarity with members of the lipid transfer (LT)/lipopolysaccharide (LPS)-binding protein (LBP) family. All LT/LBP proteins are capable of binding phospholipids and LPS. Some are involved in lipid transfer and metabolism (e.g., CETP), and others are involved in host response to gram-negative bacterial infection (e.g., BPI) (summary by Mulero et al., 2002).
ENSBTAG00000010112	62877511-62892488	BPI fold containing family B, member 6	BPIFB6	BPI = bactericidal/permeability increasing
ENSBTAG000	62901440-	BPI fold con-	BPIFB3	

00038687	62918251	taining family B, member 3		
ENSBTAG000 00038412	62927643- 62950669	BPI fold con- taining family B, member 4	BPIFB4	
	63.0 Mb	Uncharacter- ized protein		Blast shows similarity to "SPLUNC6" and "+l89". This seems related to BPI.

BTA16 (48-55 Mb)

The most significant SNP for each of the nine mastitis related traits for the targeted region of BTA16 are presented in table 18. The targeted region on BTA16 was 7 Mb. The manhattan plot for this region is presented in the figure 21.

Table 18. The most significant SNP association for nine mastitis traits in the targeted region on BTA16

Trait	SNP name	SNP posi- tion (Bp)	MAF	b- value	SE	- log ₁₀ (p- value)	Genotype	Allele increasing mastitis resistance
CM11	Chr16_50529178	50529178	0.019	28.704	3.628	14.51	G/A	A
CM12	Chr16_49054912	49054912	0.282	1.504	0.250	8.72	C/T	T
CM2	Chr16_49054912	49054912	0.282	1.416	0.259	7.34	C/T	T
CM3	Chr16_54246279	54246279	0.241	1.308	0.228	8.01	C/A	A
CM	Chr16_50532600	50532600	0.306	1.663	0.250	10.49	C/A	A
SCS1	Chr16_52097973	52097973	0.052	11.676	1.849	9.53	C/A	A
SCS2	Chr16_53806663	53806663	0.449	1.317	0.233	7.78	C/G	G
SCS3	Chr16_53806663	53806663	0.449	1.260	0.234	6.61	C/G	G
SCS	Chr16_53998150	53998150	0.169	6.124	1.022	8.66	C/T	T

Candidate polymorphism for BTA16 targeted region

The candidate SNPs for the targeted region on BTA16 which showed strong association across several mastitis related traits are presented in Table 19. The SNP at 50,529,178 showed the strong as-

sociation followed by two more SNPs (50,564,280 and 50,573,032) across several traits. Besides these three candidates, there is a non-synonymous polymorphism at 50,529,395 (alt 8%) located in the gene ENSBTAG00000020014. Downstream there are candidates in ENSBTAG00000004738 at 50,546,994 (alt 45%) (non-synonymous), and a splice-site polymorphism at 50,547,815 (alt 78%).

Table 19. Association results for the strongest polymorphisms from annotation with clinical mastitis traits on BTA16.

SNP name	SNP position (Bp)	trait	MAF	$-\log_{10}(\text{p-value})$	Genotype	Allele increasing mastitis resistance
Chr16_50529178	50529178	CM11	0.019	14.51	G/A	A
Chr16_50529178	50529178	CM12	0.019	8.39		
Chr16_50529178	50529178	CM2	0.019	6.21	G/A	A
Chr16_50529178	50529178	CM3	0.019	7.30	G/A	A
Chr16_50529178	50529178	CM	0.019	10.25	G/A	A
Chr16_50529178	50529178	SCS1	0.019	7.79	G/A	A
Chr16_50529178	50529178	SCS2	0.019	5.65	G/A	A
Chr16_50529178	50529178	SCS3	0.019	3.74	G/A	A
Chr16_50529178	50529178	SCS	0.019	7.91	G/A	A
Chr16_50564280	50564280	CM11	0.248	9.32	C/T	T
Chr16_50564280	50564280	CM12	0.248	7.56	C/T	T
Chr16_50564280	50564280	CM2	0.248	6.60	C/T	T
Chr16_50564280	50564280	CM3	0.248	7.07	C/T	T
Chr16_50564280	50564280	CM	0.248	8.96	C/T	T
Chr16_50564280	50564280	SCS1	0.248	6.30	C/T	T
Chr16_50564280	50564280	SCS2	0.248	5.11	C/T	T
Chr16_50564280	50564280	SCS3	0.248	3.80	C/T	T
Chr16_50564280	50564280	SCS	0.248	6.55	C/T	T

Chr16_50573032	50573032	CM11	0.254	10.49	G/T	T
Chr16_50573032	50573032	CM12	0.254	8.08	G/T	T
Chr16_50573032	50573032	CM2	0.254	6.92	G/T	T
Chr16_50573032	50573032	CM3	0.254	7.55	G/T	T
Chr16_50573032	50573032	CM	0.254	9.68	G/T	T
Chr16_50573032	50573032	SCS1	0.254	6.85	G/T	T
Chr16_50573032	50573032	SCS2	0.254	5.50	G/T	T
Chr16_50573032	50573032	SCS3	0.254	3.94	G/T	T
Chr16_50573032	50573032	SCS	0.254	7.12	G/T	T

Table 20. BTA16: Genes associated with mastitis according to the present analysis.

Ensembl Gene ID	Location	Gene name	Short name	Comments
ENSBTAG00000024663	49272707-49285532	Ladinin 1	LAD1	Ladinin is an anchoring filament protein of basement membrane at the dermal-epidermal junction. Human ladinin is an autoantigen associated with linear IgA disease
ENSBTAG00000016057	49332770-49353517	Cysteine and glycine-rich protein 1	CSRP1	CSRP1 is a member of the CSRP family of genes encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. The LIM/double zinc-finger motif found in CRP1 is found in a group of proteins with critical functions in gene regulation, cell growth, and somatic differentiation
ENSBTAG00000010732	52260743-52263073	matrix metalloproteinase-23 precursor	MMP23B	The MMPs belong to a larger family of proteases known as the metzincin superfamily. Collectively they are capable of degrading all kinds of extracellular matrix

				proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine in/activation. MMPs are also thought to play a major role on cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis and host defense. In humans duplicated (MMP and CDC2) in a tail to tail fashion. Apparently not in cattle.
ENSBTAG000 00015635	52484468- 52487309	tumor necrosis factor receptor superfamily member 4	TNFRSF 4	<u>Although several membrane receptors impact NF-kappaB activation, signaling from OX40 (CD134, TNFRSF4), a member of the tumor necrosis factor receptor (TNFR) superfamily, has proven to be important for T cell immunity and a strong contributor to NF-kappaB activity.</u>
ENSBTAG000 00015632	52492065- 52494746	tumor necrosis factor receptor superfamily, member 18	TNFSRF 18	
ENSBTAG000 00014707	52714627- 52715665	Ubiquitin-like protein ISG15	ISG15	ISG15 is secreted from monocytes in response to type I IFNs and causes natural killer (NK)-cell proliferation and an augmentation of non-MCH (major histocompatibility complex)-restricted cytotoxicity. ISG15 contains a unique subtype of IFN-stimulated response element (ISRE)

				that allows the binding of both PU.1 and IRFs and the synergistic activation of the element by the heterocomplex.
	52.7	Uncharacterized protein C1orf170 homolog		Blast showed weak similarity to "igA FC receptor (Streptococcus) surface proteinPspC (Streptococcus)". If there is a significant resemblance to the presenting molecule in Streptococcus, there might be a relation to the immune defense recognition of streptococcus or other bacteria.
ENSBTAG00000014537	52748704-52755937	pleckstrin homology domain containing, family N member 1	PLEKHN1	Some of the PLEKH (not necessarily family N member 1) proteins are involved in the signaling pathway of NFKB1 which have been detected in cell types expressing cytokines, chemokines and acute phase proteins. The involvement in the acute response can therefore not be ruled out.
	53.1	Uncharacterized protein		BLAST shows similarity to PLEKHM2. Some of the PLEKH (not necessarily family M member 2) proteins are involved in the signaling pathway of NFKB1 which have been detected in cell types expressing cytokines, chemokines and acute phase proteins. The involvement in the acute response can therefore not be ruled out.
ENSBTAG00000037523	52467804-52468793	UDP-Gal:betaGal beta 1,3-galactosyl-	B3GALT6	There is no info onB3GALT6 but other members of the family are interesting. B3GALT5:Sequence analysis revealed that the predicted 310-amino acid protein

		transferase polypeptide 6		is a type II membrane protein, like other glycosyltransferases. It has been demonstrated that the beta-3-GalT5 enzyme is the most probable candidate for the synthesis of type 1 Lewis antigens in gastrointestinal and pancreatic cancers. B3GALT3 encodes beta-1,3-N-acetylgalactosaminyltransferase (EC 2.4.1.79), an enzyme that catalyzes the addition of GalNAc onto globotriaosylceramide (GB3), the P(k) blood group antigen, to form GB4, the P blood group antigen. P(k) is synthesized by alpha-1,4-galactosyltransferase (A4GALT).
--	--	---------------------------	--	---

BTA19 (55-58 Mb)

The most significant SNP for each of the nine mastitis related traits for the targeted region of BTA19 are presented in table 21. The targeted region on BTA19 was 3 Mb. The manhattan plot for this region is presented in the figure 22.

Table 21. The most significant SNP association for nine mastitis traits in the targeted region on BTA19

Trait	SNP name	SNP position (Bp)	MAF	b-value	SE	-log ₁₀ (p-value)	Genotype	Allele increasing mastitis resistance
CM11	Chr19_57164311	57164311	0.293	-2.377	0.463	6.53	G/A	G
CM12	Chr19_55461224	55461224	0.418	8.581	1.74	6.05	A/C	C
CM2	BovineHD1900015719	55615219	0.245	1.295	0.251	6.57	G/A	A
CM3	Chr19_57418222	57418222	0.350	-1.154	0.227	6.43	A/G	A
CM	BovineHD1900015719	55615219	0.245	1.246	0.234	6.95	G/A	A

SCS1	Chr19_55296191	55296191	0.380	- 1.632	0.253	9.90	T/G	T
SCS2	Chr19_55296191	55296191	0.380	- 1.786	0.266	10.71	T/G	T
SCS3	Chr19_55296191	55296191	0.380	- 1.883	0.278	10.90	T/G	T
SCS	Chr19_55296191	55296191	0.380	- 1.632	0.251	10.03	T/G	T

Polymorphism associated with mastitis resistance in the targeted BTA19:

Downstream ENSBTAG00000013677 starts around 55,324,679 Bp (alt 72%). There are splice-site variants at 55,331,001 (alt 21%) and 55,338,316 (alt 64%). ENSBTAG00000044443 starts around 55,414,846 (not included in the association analyses). There is a variant in a non-coding gene at 55,419,720 (alt 29%). Upstream ENSBTAG00000002633 starts around 55,158,662 without any interesting polymorphisms. None of the above SNP selected from the functional annotation showed strong association signal across mastitis traits.

Table 22. BTA19: Genes associated with mastitis according to the present analysis.

Ensemble Id	Gene location (UMD3.1)	Common Gene Name	Preliminary arguments
ENSBTAG00000013677	55,328,989- 55,376,388	SEC14-like protein 1	Secretory protein expressed a.o. in saliva, breast tissue. Potential SNP with effect upon splice site variants
ENSBTAG00000005104	55,528,770-	N-acetylglucosaminyltransferase VB	functions in

	55,590,603	Ikke et standardnavn, det rigtige navn er formodentligt: ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME B; MGAT5B (comparative data)	the synthesis of complex cell surface N-glycans
ENSBTAG00000044443	55,419,632-55,419,819	Small Cajal body specific RNA 16	Little info

BTA20 (32-40 Mb)

The most significant SNP for each of the nine mastitis related traits for the targeted region of BTA20 are presented in table 23. The targeted region on BTA20 was 8 Mb. The manhattan plot for this region is presented in the figure 6.

Table 23. The most significant SNP association for nine mastitis traits in the targeted region on BTA20

Trait	Top-SNP	Position (Bp)	MAF	b-value	SE	-log ₁₀ (p-value)	Genotype	Allele increasing mastitis resistance
CM11	Chr20_34269660	34269660	0.457	2.196	0.297	12.81	T/C	C
CM12	Chr20_35965955	35965955	0.203	2.184	0.280	14.14	G/A	A
CM2	Chr20_35965955	35965955	0.203	2.344	0.289	15.24	G/A	A
CM3	Chr20_35914181	35914181	0.241	-1.867	0.244	13.59	G/A	G
CM	Chr20_35965955	35965955	0.203	2.095	0.268	14.17	G/A	A
SCS1	Chr20_35969130	35969130	0.315	-1.982	0.272	12.43	G/A	G
SCS2	Chr20_35865606	35865606	0.328	-1.861	0.250	12.98	G/T	G
SCS3	Chr20_35914086	35914086	0.086	-22.328	2.938	13.45	A/C	A
SCS	Chr20_35543794	35543794	0.323	1.859	0.250	12.96	A/G	G

Polymorphism associated with mastitis resistance in the targeted BTA20 region:
There are two interesting candidate polymorphic variants at 35,965,955 and 35,965,956. The association results points toward the SNP at 35,965,955 which showed strong association with all the nine

traits analyzed (Table 24). In ENSBTAG00000010423 there is a non-synonymous polymorphism at 35,966,158 (alt 52%). There are also candidate polymorphism at 35,942,954 (tri-allelic indel+snp, polymorphic) and 35,942,739 (alt 52%) and a splice-site polymorphism at 35,938,178 (alt 2%). There is another non-synonymous one at 35,922,233 (alt 4%), Another gene (ENSBTAG00000019595) starts around 35.994.141. There are non-synonymous variants at, 36,011,203 (alt 84%) and 36,013,931 (alt 73%). There is a splice-site polymorphism at 36,011,211 (alt 83%). Combining the association results and functional annotation the SNP Chr20_35965955 emerges as the strongest candidate polymorphism located with the targeted region on BTA20 affecting mastitis traits.

Table 24. The association results for the strongest polymorphism from annotation with clinical mastitis traits on BTA20.

SNP-name	SNP position (BP)	trait	MAF	$-\log_{10}(\text{p-value})$	Genotype	Allele increasing mastitis resistance
Chr20_35965955	35965955	CM11	0.203	8.93	G/A	A
Chr20_35965955	35965955	CM12	0.203	14.14	G/A	A
Chr20_35965955	35965955	CM2	0.203	15.24	G/A	A
Chr20_35965955	35965955	CM3	0.203	13.25	G/A	A
Chr20_35965955	35965955	CM	0.203	14.17	G/A	A
Chr20_35965955	35965955	SCS1	0.203	10.68	G/A	A
Chr20_35965955	35965955	SCS2	0.203	12.33	G/A	A
Chr20_35965955	35965955	SCS3	0.203	12.73	G/A	A
Chr20_35965955	35965955	SCS	0.203	11.70	G/A	A

Table 25. BTA20: Genes associated with mastitis according to the present analysis.

Ensemble Id	Gene location (UMD3.1)	Common Gene Name	Preliminary arguments
ENSBTAG00000010423	35,917,479-35,966,671	LIFR- Leukemia Inhibitory Factor Receptor Alpha	Involved in acute phase response (links to prolactinoma), expressed in saliva, mammary gland

			Two ns-SNPs (one with alt 52% in pos. 35.966.158 very interesting)
ENSBTAG00000014972	33,762,479-33,774,648	Prostaglandin E2 receptor EP4 subtype	EP4R regulates intestinal homeostasis by maintaining mucosal integrity and downregulating the immune response.
ENSBTAG00000016149	35,092,195-35,158,959	Complement component C9	Complement factor
ENSBTAG00000006697	35,376,524-35,514,741	RICTOR	Components of a protein complex that integrates nutrient- and growth factor-derived signals to regulate cell growth
ENSBTAG00000033107	35,521,410-35,588,186	OSMR- ON-COSTATIN M RECEPTOR	Epithelial expression, involved in inflammation
ENSBTAG00000011766	33,549,495-33,606,517	Complement component C7 precursor	Complement factor
ENSBTAG00000014177	33,328,558-33,405,555	complement component C6 precursor	Complement factor

Example 5

Causative polymorphism for BTA6 mastitis QTL

The missense mutation, rs110326785 (G/A) in the neuropeptide FF receptor 2 gene (NPFFR2) is associated with a mastitis QTL on BTA6. This SNP located at 89,059,253 Bp (UMD3.1) causes an amino acid change 392 E to K (Glutamic acid to Lysine). The minor allele frequency of rs110326785 in Nordic Holstein is 48.3%. The allele substitution effects for nine mastitis traits in Holstein are given in the below table 26. This SNP (rs110326785) is also segregating in Nordic Red cattle population (MAF = 41.2%) with allele substitution effect of -2.68 (se = 0.26) for the breeding value for mastitis index and it

explained 2.58% of the genetic variance. This confirms its effect in the same direction in both Holstein and Nordic Red, i.e. the allele A is reducing the resistance to mastitis in both the populations.

Table. 26 Effect of SNP, rs110326785, on nine mastitis traits in Nordic Holstein population

trait	MAF	Allele substitution effect	S.E.	P-value	Percent of genetic variance explained
CM11	0.48	-3.16	0.24	3.93e-38	5.14
CM12	0.48	-2.43	0.25	2.11e-22	3.00
CM2	0.48	-2.54	0.26	8.30e-23	3.26
CM3	0.48	-2.77	0.24	4.52e-30	4.02
CM-index	0.48	-2.82	0.24	2.39e-31	4.09
SCS1	0.48	-1.41	0.26	4.04e-08	0.91
SCS2	0.48	-1.51	0.27	2.78e-08	1.04
SCS3	0.48	-1.53	0.28	6.12e-08	1.10
SCS-index	0.48	-1.49	0.26	5.03e-09	1.02

Example 6

Polymorphism for BTA20 mastitis QTL

The SNP, rs133218364, is a synonymous variant within Caspase recruitment domain-containing protein 6 gene (CARD6) showed most significant association with clinical mastitis index in Holstein cattle. This SNP is located at 33,642,072 Bp on BTA20. Similarly, another SNP, rs133596506, (at 35969994 Bp) located 3323 Bp downstream to LIFR gene (Leukemia inhibitory factor receptor) also showed very high significant association with clinical mastitis index. These two variants were fitted as fixed effect in a haplotype-based analysis using 50K genotype. The variant rs133218364 was able to explain the total QTL variance for the targeted region on BTA20 (green line in the Figure below). However, rs133218364 being a synonymous variant does not change the amino acid composition of the protein. Therefore, rs133218364 is not likely the causative polymorphism underlying the QTL, but is in perfect

linkage disequilibrium with the causative polymorphism. The rs133596506 located close to LIFR gene also when included in the haplotype model resulted in a substantial decrease in test statistic

Sequences

SEQ ID NO: 1

NPFFR2 gene – coding region

NCBI Reference Sequence: AC_000163.1

GenBankGraphics

>gi|258513361:89052219-89059482 Bos taurus breed Hereford chromosome 6,
Bos_taurus_UMD_3.1, whole genome shotgun sequence, having the G-allele of the G/A SNP located
at 89,059,253.

ATGAGTGAGGAATGGGATTCAAACCTCTACAGAAAACCTGGCATTACATTTGGAA-
TAATGCCACAACACATGATCTGTACTCAGATATCAATATTACCTATGTGAACTACTA-
TCTTCACCAGCCTCAAGTGGCAGCGATTTTCATTATTTCTACTTTTTTGATCTTCTTCC-
TATGCATGGTGGGAAACACAGTGGTTTGCTTCATTGTAATGAGGAACAAACAT-
ATGCACACAGTCACTAATCTCTTCATCTTGAACCTGGCCATAAGTGATCTACTAGTTGG-
TATATTCTGTATGCCTATCACACTGCTGGACAATATTATAGCAGGTATGTTGATCCACTCCAG-
TATTCTTGCCTGGAAAATCCCATGGATGGAGGAGCCTGGTGGGCTACAGTC-
TATGGGGTCACAAACAGCTGGAAATGACTGAGTGACTTCACTTATGTTGATTTGTG-
TACAGCTCAAAGATAATATAAAAAAATATTTGTCCCATATCCCTGCAGCTATGGTACAG-
TCATCCATTCATTTCAAATATTTACGGAGTTCCAA-
GAACTTCTCCAAGTAGCTGTCCTCATGAGGCCTACATTATAAAGGAGGA-
TAAAAAAACAACAAACAAAAAACTATATAAACAGAGAATAAAAAGAATTATGGG-
GAAAAGTAAAGCAAGTGACAGAGATGAGATGTGGAGGCTGATTTTTATAGAGTTCACTGAC-
GGTCATCCATGAATGATGACACTTCTTACTGAAGACTATGAATTTCTTGGCAGTTCTGAG-
CACATATAGTATGGTAGGAATGTTATTGAGACTATATGCATCATAAAGCTCTAA-
GAACTGCTAAGTGTGGTTTCCATTAATATGATGTCTTCAATATAACGTAAATAGATATTTA-
GACCCTCTTGTGGTTAGCTGGGCTTCTCTGGTGGTTGGGAGATTTCCAACAGTTTTT-
GATGGAAGGCAAGCAGCAGGACCAATGATATGTCACAAAGTGGTAGTTTCATTCATGGAGTAG-
TAATTTACATGTGCAACATAACAATGGTTCGGGTGCTACCCTAGAGGACTTCCAGGTCCG-
TATTACCACTTCCTAACACAACCTTTATGTCCCTCTCTTGTGGCTCAGCTGGTAAA-
GAATCCACCTGTAATCAATCCCTGGGTTGGGAAGATTCCCCTGGAGGATGACATGG-
CAACCCACTCTAGTTTTCTTGTCTGGAAAATCCCCATGGACAGAAGAGCCTGGCAGGCTG-

CAGTCCATGGGGTCACAAACAGTTGGACACAACCTGAGCGACCAAGCACAAAACATCACATTA-
TATACCCCAGAAGTATAGGAATGGTGTATCTATGGCTCCTGGTAGAGTTTTGG-
TACATAGTACCTGATTAATAAATATTTGTTGTACAACTAATGAATAGCACTCAAGATACTCA-
TATTCCAAATCTGTATAAGAAAATATAAAAAGTATTTAGATCAAACAAGCCATATCATGGGGC-
TACTGTGGTGGCTCAGGAGTAAAGAATTTGCCTGCAATGCAGGAGATGCAGA-
GATGTGGGTTCAATCCCTGGGTCGGAAAGATTCCCTGAAGGAGAAAATGGCAACCCACTCCAG-
TAATCTTGCCCAGAAAGTAACTGATGTTGAATGCCACAAAAGGGAAA-
GAACTGTGGTGTGGTTTGTGTTACTGCTGTGTAGTCAGACACGACTGAGTGAATAACAA-
TAATAACACAAGTCATATCACAGTTCTTTTCCATTATGG-
CATTCAACATAGGTTTACTGAAAAATGGAGATTTAA-
GAATTTATTTCTGTTTCTTTCCTTTCTCTGAAGTGGGAGTCAGGGAATGTTTGAGTGGC-
TATTCTATCATAATACTACATAAATTCTGTGTTTCCATGATGCTTGTCATTTAAAAGCAA-
TATTTATTAATGATGTACATTTAAAAAAAATGATGTACATTTTTAAGATGTGCTAGACAAAAA-
GAGTTGATAAAAATTGTTGTCTCAATAAACTTAAGAAATGATCTCAATATGTCTCCCATAAA-
TATCTATAATTAAATTACTAGTTAAGTTTTTTTCATATACAGTATCCTTCCCTACCCCTGAT-
TCCTATTCCCAGGAGGCAGCCACATTCAGCATTTTTGCATTTATTTTTGGTAATTACTATAA-
TATTTCTGAATAACATGTTTTTATTCTAGTATATTATCCAACCTGCAGAAGATGCAATTTAG-
TTCTCATTATCCTCTTCTACCCCAAGAGATAGTTTCCCTCACCAAACCTCCACTGAACTGACAG-
CACTAGGGCAAAAGAATGTAAATCCATAGAACTGTCTGAATGTGAAATT-
GGAAAAACAACATGACTGGTTGAAATTTGGTATAAATACCAACAGACACATTTATA-
CAGAGCCACAAATATACATTCATTTTTTCACCTCCCTCATTCTCTCAATATGAGCACGTCATT-
GTTTTTTGTTAAATCAATATTTAGGGTATGCATTACTATTATTATATGTAC-
CTTACCCCTGCTGAACCATGTAGAGTACTATGATAGCAAC-
CTTTTCTCTTATAAAATGTTTTTGTTCCTGGATTTAATAAGGGCATAATCTTTTGATTT-
GTTAATGTTTTGAGTATAGCTATCAATAATGTTTTCTCAGATTTTCTTCCAGGAGAG-
TTAAGTTTCTTGCCAATACCTTCAAACATATAAAGTACATA-
TATGTGTTTTTAACACATCAAAAAGATGTAAATGAGGTGAATAATAAAGCTTCCAAGCTT-
GTTGTGGGGATTAGATATGTTAATAGATGCAAAATATTTATTAGAGCATATAGAATGTT-
GAACTACTGTATAAGCTTTGACATTATTAATACTGAAAAACAAA-
GCTCTAAATATATTAATGAAAATAATGGGAAATGTTGATTGTTCCCTGGATCTTTTAG-
GAAACAGTTACATGCATCTAATTTTCATGTCTTTCTCTTCAAAATTTTCAGTGAAATTAAAA-
TATACATGTATGATCTCTCTGAAGACTAACTGTTCCATTTCCCTTTCAGGATGGCCTTTT-

GGAAGTACAATGTGCAAGATCAGTGGCTTGGTTCAGGGAATATCTGTT-
GCGGCTTCTGTCTTTACTTTAGTTGCAATAGCAGTGGA-
TAGGTAGGTCAACCCCAAACCTCTGAATCCAGAAAATTGAGCATGTCTGCAACTATTCTAC-
CTAACCAGTGAAAAATGTGTCATCTACTACATTTGGGCATATCTGTTTAAAATT-
GTATTCATAATATATCCTTTTATATATATATATATATGTAGTATATAATATATATACAT-
ATGCATAGTATATATGTGTGTGTATATATATTTGTGCATTATATATACATAAATT-
GTATCCACAGTATGTATCCCTTTATATATATATATATATAGAGAGAGAGAGAGAGGGAGA-
TAGGGTGTATGCATGTGCATGCTCAGTTACTCAGTCATTTCTGATTCTTTGTGAC-
CACATGGACTGTGGCCTGCCAAGTTCCTCTGTCCATGGAATTTTCTAGGCAAGAATACTG-
GAGTGGGTTGCCATTTCTACTCCAGGG-
GATCTTCCTGAGCCAGGGATCAAACCCATGCCTCCTGCATTTGCAGGAGCATTCTTTACCAC-
TGCACCACCTGAGAAACCACACACACACACACACACTAAGAGTTCAGTAATAAAATAAAAC-
TAGTAAAGTTTTTCATATTTTAAAATTAAATAATTAGAGATGATTCATGTCCTAGTTT-
GGCCTGCTATAACAAGGTATAATACGTTATTTGATGAATGAATAAATGAAAAATAATACTT-
GAAGTTTCCATAATTGTTTTACAAAAGGAGCAAAAATACCTAGAACAGCAC-
CTATGAAGTTATCCGTAATTTAAGGGTGAGTAAATGGGAGAATTCAGTATTAGAAAGACTA-
GATGAACACTTGGAGGTTAAGACAGAAGACCTATCACTTCATGGAAAATAGATGG-
GAACAAAGTAGAAACAGTGGCAGATTTTATTTTCTTGGATTCCAAAATCACTGTG-
GATGGTGACCACAGCCACGAAATGAAATGATGCTTGCTTCTTGGAAGTTACAAGGGAA-
GCCTGGTGACAAACCTATACAGTGTATTACAAAGCAGAGACATCACTTTGTG-
GACAAAACCTCACATAGTCCAACCTATGGTTTTTCCAGTAGTCCTCTAGGGATGTGAGAGTT-
GGACCATGAAGAAGGCTGAGAGCCAAAGAATTGATGCTTTAGAACTGTGCTGCTGGAGAA-
GACTCTTGAGAGTTCTTGGACTGCAAAGAGATCAAACCAGTCAATCCTAAAGGAAATCAAC-
CGTGAATATTCATTGGAAGGACTGATGCTGAAGCTGAAACTACAATTGATGTGAAGAAC-
CAACTCATTGGAAAACACTCTGATGCTGGGAAAGATTGAGGGCAGGAGGA-
GAAGTGGGTGACAGAGAATTAGATGGTTGGAGAGCTTCACCGACTCAATGGAGATGAAATT-
GAACAAACTCTGGGAGATAGTGGAGGACAGAGAAGCCTAGCGTGGTGCAGTCCATGGGGTT-
GCAAAGAGCTGAACACAACCTTAGCAACTGAGCAACAACAAAAACAAGACTTTACATATGCTTT-
GAAGGAGTTGTAAAGAAAGACAACAGAGTAGTAAAAGCTCAAGCTAACTAGTCGTTATATAAA-
GATATTAGATAAATTAGTTTGGGTTGCTTCTAAGCCATTTAAAACTCTGTTTTCTTACCTG-
CAGATCTGGAAAACAGTAAGTTTCATAACATTTAGTTTTATAGAGTCATCAAAAAATCCTA-
GAAAATTCAATAGATGATAATACTTTGAAAATGTGTTATGCAGTTGCATAGTT-

GTATGGTTATCTTATACTGCAGAAGGAAATGGCAACCCAGTCCAGTATTCTTGCCTG-
GAAAATTCCATGGAAAGAGGAGCCTGGCAGGCTACAGTTCATGAGGTCACAAAGAGTCAGA-
CATGACTGAATGACTGAGCACATGGTTATCTTATAATGAACATAATGAACATCAATAA-
TAACATTAAGAATCACAATGACAAAAATTAACAGCAGTAAAATGAACCAG-
TGTTACTCTTCATATTGATGTTGAATTTTCATGCTCCTTAGAAGATATGGAACACCAG-
GAAGGTGTATAAACAGAACTCATAATTGGCAACTCTCAGAGTCTTACAGCTCTGAAAAAAC-
CACCAAGACACTTGGTGGCTCAAAACAGCAGTGTTCAGTACTTCCCACAACTCTG-
TAGATTGGCTGGGTGTGGTTCTCCTACTCTATGTCTTATAGCTGAAATT-
GCTCATGCTTCCACTTATAACCATGCTTGCTAATGTTCAACTAACTGGCCAAAGCAAATT-
GCATGTCCAAGCACACAGATCATATGTGAGGGGACCACAGAAGGGGCATGAAGGAAAGTATAA-
GAATATGGGCTCTGGAGCCAAACCACATGTGCAACAATCATGTGTGATTATGGGCAA-
GAATTTTTACCCTTTCTAAGACTTTTCCCCATAAAAGGCTTAAAGATACAATCCATGCAAAC-
CAATGAAAAGGACCTTAGAACAGAATATTAAATGTTCAATATGGGCTGCTTAACAC-
TAACATTTTTATTATAACTTTAAAATTTTTATTGGAGTAGAGTTGATTTACAATGTT-
GTGTTAATTTCTGCTATACAGAAAAGTGAATCAGTTGTAAATACATATGCATA-
CATCCGTGCTTTTTTTCTAAAGGTTTATTGTATTTATTTATTTAATTTACTTTTT-
GGCTGTGCTGGGTCTTCGTTGCTGTGCATAGGCTTTTCTCTAACTGCAGCGAGTGGGGC-
TACTCTCCGTTGTGATGCACAGGCTTCTTGTTGCAGCAGCTTCTCTTGTTACGGAGCACAG-
GATCTAGGTGCGCAGGTTTCAGTAGCTGCAGCACATGGGCTCTGTAATT-
GTGGTTCACAGGCTCTAGACGCTGGCTCAGTAGTTGTGATGCATCAACTTAGCCACTCTGCGG-
CATGTGAGATCCTCCCAGACCAGGGATCAAACCAGCATCCCTTGCACTGCAAGACGGAT-
TCCTAATCGCTGGACCACCAGGGAAGCCTGAGTACTTTTACTATTAATAGTGTCTGATA-
TACTCCACTTATTCGTATTTTGAGTTGAAATTAATCTCATATAA-
TAATTACAGAAAATGCGTCTCTCCTAATTCTAACTTTCTACATTTTAGGGAGAACGTG-
GATGAAGACTGCAGTTACTGAAATTTAATTAATGACTCAGCCAGAAGTTATGAGCAG-
TCCTTCACTGATATTTGCCTTTTCGTTACAGGTTCCGGTGTGTCATCTACCCTTTTAAAC-
CAAAGCTCACTATCAAGACGGCGTTTGTGCATCATTATGATTATCTGGGTCCTGGCCATT-
GCCATCATGTCCCCATCTGCAGTAATGTTACATGTACAGGAAGAAAAAATTACCGAGTGA-
GATTCAACTCCCAGGATAAAACCAGCCCAGTCTACTGGTGCCGGGAAGACTGGCCAAGTCAG-
GAAATGAGGAGGATTTATAACCACAGTGCTGTTTGCCAATATCTAC-
CTGGCTCCCCTGTCCCTCATTGTCATCATGTATGGAAGGATTGGAATTTCACTGTTCAAGAG-
GAAAGTGCCCCACACAGGCAAACAGAACCGGGAGCAGTGGCATGTGGTATCCAAGAAGAA-

86

GCAGAAGATCATTAAGATGCTCCTGACCGTGGCTCTGCTTTTCATTCTCTCCTGGTT-
GCCCCTGTGGACCCTGATGATGCTCTCAGATTATGTTGACCTGTCTGCAAATGAACTG-
CAGGTCATCAATATCTACATCTACCCTTTTGCACACTGGCTGGCCTTCTGCAACAG-
CAGCGTCAACCCCATCATTTATGGTTTCTTCAATGAAAATTTTCGTCGTGGTTTCCAA-
GATGCTTTTTCACCTCCAGCTCTGCCAAAAAAGAGCAAAGTCCAAGGAAGTCTACACTCTGA-
GAGCTAAAAACACTGTGGTCATCAACACATCTCATCTGTCAGCACAGGAATCAACAG-
TTAAAAACCCACACGAGGAAACTGTGCTTTGTAGGATAAGTGCTGAAAAGCCCTTACAGGAAT-
TAATGATGGAAGAATTAGGAGAAATTACCAGTAGCAATGAGATGTAAAAA-
GAGCTGGTGTGATGATTTTAACTCTGCTGTGTGATATATATTGAAATATTGTTGATGTC-
TATGGCTTCGTTCTTTAGTTCTTTCTATGAATGTTA-
GAAACCCTCTCTGAAAAAAAGTCAACAAAATGAACC

SEQ ID NO: 2

rs133218364 SNP

Original source

Variants (including SNPs and indels) imported from dbSNP (release 137)

Alleles

Reference/Alternative: T/C | Ambiguity code: Y

Location

Chromosome **20:33640072** (forward strand)

Synonyms

None currently in the database

HGVS names

This variation has **2** HGVS names - click the plus to show

Flanking sequence

The sequence below is from the **reference genome** flanking the variant location. The variant is shown in **bold underlined (Y)**. The Y position can be T/C.

Neighbouring variants are shown with highlighted letters and ambiguity codes (R and K). R is a G/A variant; K is a G/T variant.

87

TAGATTGGGAGGACTGGGGCTGGCATGGCTTGGGCTGAGTGGATTTGGATGGCGAACTTT
CAGCTCGGGGGRCCTGGTGCTGAGTGGGCTTGGTTTGAGTGGGTTTGGGTTGAAAGGGCA
CAGGTTGGGAGGGTTTGTGCTGGGACTGTTTGACCTGGGGTGACTTGTGCTGATTAGGTC
TGAATTGAGAGCTGGGCAAATACATGCTGTAGGACATAGGATGGAATCCCATTTGGAAAG
ATGGATTTGAAGGCCACCTTGTGTCTTCAGCTTAGCTCCTTGCTGAGGGGGCAGTCCTTC
TTGGTTTTTGTGTGGCTCCTGCTGCTTGAAAGGCTTGATGATGAGGATTTTCAATATGGG
GTTTTGTTCTCATGGATGTTCTCACTGTCTCTGTTGGCTTYGTTCCCCTGGCACTGACTT
GCCCAGGCTTCCCAACTGCTCCTCCTGGCCATGAACCCAGGGAATGGAGGTGACCTACCT
GGGAGTCCTCTTTCCCAGACCTTTCAAGGGTTCCTATTGTCTGTGGTCTCTGAGGCCAGG
CCGGTATATGCTGAGACATGGGTCTTGGTGGTCTCCCAAAGTTCTACCCATGTGATGTC
TCCAAGGAGTTCCTGAAAATCTCATAAATGTTTCACCTGAATAAAATCTCTGGGGCTGGA
AATATTGAATTCCAAAACGTTTGCCTGGACTATGTGCCCTTGTATTCTGAAAGGGCAAAG
GATGGAACCTCTTAGGCCTCTGCTGTAACCAGAAGCKGGAGCCCATAGCCCAAGGGGCTT
TCAAAGAAACATGGTTAAAGT

SEQ ID NO: 3

rs133596506 SNP

Original source

Variants (including SNPs and indels) imported from dbSNP (release 137)

Alleles

Reference/Alternative: **T/C** | Ambiguity code: **Y**

Location

Chromosome **20:35969994** (forward strand)

Evidence status



Synonyms

None currently in the database

HGVS name

20:g.35969994T>C

Flanking sequence

The sequence below is from the **reference genome** flanking the variant location. The variant is shown in **bold underlined (Y)**. The Y position can be T/C.

Neighbouring variants are shown with underlined letters and ambiguity codes (Y, R, S). The TC underlined is a TC/– indel variant; R is a G/A variant; S is a G/C variant.

CCTTATTA ACTGCGTATTGCATGGACTAGCATCYGTATACAATTGAAGTCTTCAGTGTGC
TAAACCTGTAGGAGCCTGGGTTTGACATTGTGGCCCAAATATCTGAATAGTTGGGTGTTT
ATGTGCTTCAGTGATAGAGGTGCTCCATCCCTGCAGTTTACACAGAGTGGCARCGATTCC
CAGAAAAATTTACAGGCAGGAGYTTTCAGCCTCATTTCATACCAGCATTGCTTTTCACGG
CTCATGGATCTGAAGGATTGCATTGAGAACATCTAGTCCTATTGCACTCTCAGAACTGT
GGGAAAAGTCATATTCTTAAACCTTCATGCAACTTGTATTCTTGTTGGAAATTAGTCCTG
TGATTTCTTAGTTGTCTTCATACTGGCCATATTTAAAGAAYATCACAGTCCTTTTTTTGTA
CTTGAATAATTAGATGTAGTTTAGTGAAGGAGACATGTGAATGTTTTCTTCCAAAAGGAA
TTTGGAATCAGTTTTAACGAGTTTGAAATAAAAGTGCTCCCTAACCTGTTAATATGCAGA
AAATATTATCTCAAATTTTTCTACTGCTGAGGCACATAATCTGATAAACTTTTTTTTTT
TTTCTTCTGTTTAAGGTAGTTTTTACTGTTTTCTGTTCTGAACCATGTTAAAATTTGTAT
ATCTTTTATAACATASATTTCCCCCCTTATTTTGAAAGTATAAAATTGGGCATCTCAAAA
GTCAAATGTGGGATCATTAGTTAATCACTAAGACTAGGCACATAATGGAAATTCAGTCAG
GTTTTTTATTGACTGAGTCCC

Claims

1. A method for determining resistance to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom, wherein said at least one genetic marker is located on BTA6 in the neuropeptide FF receptor 2 (NPFFR2) gene, and/or said at least one genetic marker is located in a region of the bovine genome selected from the group consisting of regions 1-61, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6:

1	2	3	4	5	6	9	10
Re- gion No.	Chr	Start- SNP	Start Pos.	End- SNP	End Pos.	Most sig. SNP name	Top SNP Pos
1	1	19479	76096755	19481	76099500	Bo- vineHD0100021877	76096755
2	1	24128	96507612	24500	97612639	Bo- vineHD0100027421	96507612
3	1	33740	13523619 0	35634	14179171 7	Bo- vineHD0100038448	13528594 9
4	3	16606	62218619	16846	63185254	ARS-BFGL-NGS- 57708	62615411
5	3	23488	92199528	25665	10136492 0	Bo- vineHD0300028997	10132386 6
6	4	5485	20993524	7036	27829152	Bo- vineHD0400008053	27829152
7	4	8924	36558317	10527	44073697	Hapmap24419-BTA- 162106	36558317
8	4	13365	55763368	15735	65519029	Bo- vineHD0400016706	61125903
9	4	23730	97674762	24213	99540028	Bo-	99540028

						vineHD0400027868	
10	5	16168	67417898	17489	72243381	ARS-BFGL-NGS-70198	72243381
11	5	20435	84539347	27159	10994823 2	Bo- vineHD0500024659	86998734
12	6	4475	18036724	7462	29334848	Bo- vineHD0600006497	23549700
13	6	13573	51683927	13598	51755112	Bo- vineHD0600014264	51731374
14	6	18708	71082832	26792	10275784 1	Bo- vineHD0600024355	88919352
15	7	1236	5202111	1708	6663939	Bo- vineHD0700001692	5927298
16	7	2907	14485587	4789	22681472	Bo- vineHD0700005054	18032163
17	7	7174	31432538	10157	41607314	Bo- vineHD4100005904	33485418
18	7	10795	44074131	15561	63839308	Bo- vineHD0700018462	63839308
19	7	26534	10475330 0	27857	10958467 7	Bo- vineHD0700031919	10940639 3
20	8	801	3101470	1541	5993074	Bo- vineHD0800001554	4844864
21	8	4831	20417406	8352	35930652	Bo- vineHD0800006734	22287380
22	9	1495	7453669	1591	7749361	Bo- vineHD0900001741	7735822
23	9	2848	12242079	3079	13035215	Bo- vineHD0900003387	12963863
24	9	21143	86380558	21144	86381215	Bo- vineHD0900024208	86380558

25	10	12689	47838479	13661	51407940	Bo- vineHD1000014875	49359005
26	10	15921	62168320	20229	79735238	Bo- vineHD1000021167	74285470
27	10	22654	89224445	24333	94083525	BTA-80363-no-rs	90484606
28	11	68	210963	1555	4567617	Bo- vineHD4100008447	210963
29	11	23860	88133102	24010	88778399	Bo- vineHD1100025584	88778399
30	12	787	2569573	933	2991581	Bo- vineHD1200000926	2917822
31	12	3217	11578657	7626	27097379	Bo- vineHD1200006858	22865273
32	12	11277	44331491	11285	44349649	Bo- vineHD1200012284	44331491
33	12	15918	62561736	17398	68494212	Bo- vineHD1200017277	63068164
34	13	11798	53471793	15089	70173150	Bo- vineHD1300017074	59588546
35	14	3505	13282075	5041	20691077	Bo- vineHD1400005926	20662703
36	14	9864	43961811	15451	69623868	Bo- vineHD1400014643	51548605
37	15	2329	9897946	2334	9915788	Bo- vineHD1500002610	9897946
38	15	6316	26178933	8176	33293128	Bo- vineHD1500008366	31105101
39	15	9855	39284002	13327	52111223	Bo- vineHD1500012201	43914509
40	15	17079	66540919	17084	66551171	Bo- vineHD1500019116	66543720

41	16	1694	8171169	2172	10545502	Bo- vineHD1600002326	8171169
42	16	3534	15737429	3596	16009799	Bo- vineHD1600004272	15784091
43	16	5299	21799660	16175	64955150	Bo- vineHD1600014622	52924145
44	17	512	2467836	3752	13800376	Bo- vineHD1700002674	9472006
45	17	16389	61406860	16431	61535420	ARS-BFGL-NGS- 26121	61522805
46	18	6383	21603442	6944	23535823	Bo- vineHD1800006666	21606994
47	18	11892	41653211	13902	48570545	Bo- vineHD1800013234	44778431
48	19	2020	8230088	3676	14585690	Bo- vineHD1900003860	14578566
49	19	7734	27998517	8035	29383514	Bo- vineHD1900008608	29320178
50	19	9209	33351947	12120	46467474	Bo- vineHD1900012270	43098630
51	19	12750	49013784	16762	62339802	Bo- vineHD1900015719	55615219
52	20	5111	18072225	5122	18110885	Bo- vineHD2000005443	18110885
53	20	7852	28291423	14407	55744850	Bo- vineHD2000010279	35981673
54	20	14681	56557595	19739	71359405	Bo- vineHD2000019538	67376802
55	21	11020	43772475	11021	43773986	Bo- vineHD2100012534	43772475
56	22	6727	24494154	8368	31397754	Hapmap38325-BTA-	25113789

						53915	
57	23	1077	4758944	3549	14524909	Bo- vineHD2300002833	11512182
58	23	4429	18006108	7776	28819118	Bo- vineHD2300007202	26369699
59	23	9221	33362170	9673	35604326	Bo- vineHD2300010058	34251317
60	23	11058	41491498	13747	51051152	Bo- vineHD2300012843	44312928
61	25	3879	12927936	3879	12927936	Bo- vineHD2500003616	12927936

2. The method according to claim 1, wherein said genetic marker is selected from the group consisting of most significant SNPs set forth in column 9 of the table in claim 1.
3. The method according to any of the preceding claims, wherein said genetic marker is located in a region selected from the group consisting of regions 14, 34, 43 and 53 as set forth in the table in claim 1.
4. The method according to any of the preceding claims, wherein said genetic marker is selected from the group consisting of BovineHD0600024355, BovineHD1300017074, Bo-
vineHD1600014622 and BovineHD2000010279.
5. The method according to any of the preceding claims, wherein said genetic marker is located on BTA6 in the region delineated by the SNP markers 18708 and 26792.
6. The method according to any of the preceding claims, wherein said genetic marker is located on BTA6 in the neuropeptide FF receptor 2 (NPFFR2) gene.
7. The method according to any of the preceding claims, wherein said genetic marker is the SNP BovineHD0600024355 and/or any genetic marker genetically coupled thereto.
8. The method according to any of the preceding claims, wherein said genetic marker is the G/A SNP located at 89,059,253 Bp (UMD3.1), wherein the A allele is associated with mastitis and the G allele is associated with resistance to mastitis.

9. The method according to any of the preceding claims, wherein said genetic marker is located on BTA20 in the Caspase recruitment domain-containing protein 6 (CARD6) gene, such as the rs133218364 T/C SNP, wherein the T allele is associated with mastitis and the C allele is associated with resistance to mastitis.
10. The method according to any of the preceding claims, wherein said genetic marker is located on BTA20 in a region 5000 bp downstream of the Leukemia inhibitory factor receptor (LIFR) gene, such as the rs133596506 SNP, wherein the C allele is associated with mastitis and the T allele is associated with resistance to mastitis.
11. The method according to any of the preceding claims, wherein said genetic marker is selected from the group consisting of the SNPs set forth in tables 10, 12, 13, 15, 16, 18, 19, 21, 23 and 24.
12. The method according to any of the preceding claims, wherein said genetic marker is located in a gene selected from the group consisting of the genes set forth in tables 11, 14, 17, 20, 22 and 25.
13. The method according to any of the preceding claims, wherein said trait is selected from CM11 (Clinical mastitis (1) or not (0) between -15 and 50 days after 1st calving), CM12 (Clinical mastitis (1) or not (0) between 51 and 305 days after 1st calving), CM2 (Clinical mastitis (1) or not (0) between -15 and 305 days after 2nd calving), CM3 (Clinical mastitis (1) or not (0) between -15 and 305 days after 3rd calving), CM (Clinical mastitis: $0.25 \cdot \text{CM11} + 0.25 \cdot \text{CM12} + 0.3 \cdot \text{CM2} + 0.2 \cdot \text{CM3}$), SCC1 (Log. somatic cell count average in 1st lactation), SCC2 (Log. somatic cell count average in 2nd lactation), SCC3 (Log. somatic cell count average in 3rd lactation) and SCC (Log somatic cell count: $0.5 \cdot \text{SCC1} + 0.3 \cdot \text{SCC2} + 0.2 \cdot \text{SCC3}$).
14. The method according to any of the preceding claims, wherein the at least one genetic marker indicative of mastitis resistance is used to estimate the breeding value of said bovine subject.
15. The method according to any of the preceding claims, wherein said sample is selected from blood, semen (sperm), urine, muscle, skin, hair, ear, tail, fat, and/or saliva.
16. The method according to any of the preceding claims, wherein said sample is semen (sperm) or blood.
17. The method according to any of the preceding claims, said method comprising amplifying a genetic region comprising said genetic marker and detecting said amplification product.

18. The method according to any of the preceding claims, wherein said bovine subject is a member of the Holstein breed.
19. The method according to any of the preceding claims, wherein said bovine subject is a member of the Danish Holstein cattle population.
20. The method according to any of the preceding claims, wherein said bovine subject is a member Nordic Holstein, Danish Jersey and Nordic Red breed.
21. The method according to any of the preceding claims, wherein said at least one genetic marker is at least two genetic markers, such as 3, 4, 5, 6, 7, 8, 9, for example at least 10 genetic markers.
22. A method for selecting a bovine subject for breeding purposes, said method comprising determining resistance to mastitis of said bovine subject and/or off-spring therefrom by a method as defined in any of the preceding claims.
23. The method according to claim 22, comprising estimating a breeding value of said selected bovine subject.
24. The method according to claim 23, wherein said breeding value is estimated on the basis of the presence or absence of a genetic marker as defined in any of claims 1 to 21.
25. A method for estimating a breeding value in respect of susceptibility to mastitis in a bovine subject, comprising detecting in a sample from said bovine subject the presence or absence of at least one genetic marker that is associated with at least one trait indicative of mastitis resistance of said bovine subject and/or off-spring therefrom and assigning a breeding value based on said presence or absence, wherein said at least one genetic marker is located on BTA6 in the neuropeptide FF receptor 2 (NPFFR2) gene, and/or said at least one genetic marker is located in a region of the bovine genome selected from the group consisting of regions 1-61 of the table identified in claim 1, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6.
26. The method according to claim 25, wherein said breeding value is calculated using a marker-assisted single trait Best Linear Unbiased Prediction (MA-BLUP).
27. The method according to claim 25, as further defined in any of claim 1 to 21.
28. A method for selective breeding of bovine subjects, said method comprising

- a. providing a bovine subject,
 - b. obtaining a biological sample from said subject,
 - c. determining the presence in that sample of at least one genetic marker located in a region of the bovine genome selected from the group consisting of regions 1-61 of the table identified in claim 1, wherein said regions are delineated by the SNP markers identified in columns 3 and 5, and/or delineated by the genomic position identified in columns 4 and 6,
 - d. selecting a bovine subject having in its genome said at least one genetic marker, and
 - e. using said bovine subject for breeding.
29. The method according to claim 28, said method comprising collecting semen from said selected bovine subject and using said semen for artificial insemination of one or more cows or heifers.

Clinical mastitis all lactations (CM)





Figure 1

Somatic cell score (SCS)



Chromosome

Figure 2

Figure 3

Clinical mastitis first lactation (-15 to 50 days) (CM11)




Figure 4

Clinical mastitis first lactation (51 to 305 days) (CM12)




Figure 5

Clinical mastitis second lactation (-15 to 305 days) (CM2)





Figure 6

Clinical mastitis third lactation (-15 to 305 days) (CM3)








Figure 7








Figure 10




Figure 11




Figure 12




Figure 13





Figure 14

Figure 15






Figure 16

Figure 17

Table 6

1	2	3	4	5	6	7	8	9	10	11	12
Region No.	Chr	Start-SNP	Start Pos.	End-SNP	End Pos.	Region-BP	No. Of sig. SNP	Most sig. SNP name	Top SNP Pos	-log ₁₀ (p-value)	Traits showing association
1	1	19479	76096755	19481	76099500	2745	3	BovineHD0100021877	76096755	7.12	1
2	1	24128	96507612	24500	97612639	1105027	3	BovineHD0100027421	96507612	7.64	6,1
3	1	33740	135236190	35634	141791717	6555527	6	BovineHD0100038448	135285949	10.80	1
4	3	16606	62218619	16846	63185254	966635	67	ARS-BFGL-NGS-57708	62615411	9.45	6,1
5	3	23488	92199528	25665	101364920	9165392	49	BovineHD0300028997	101323866	8.84	5,2,1,6,3,4
6	4	5485	20993524	7036	27829152	6835628	20	BovineHD0400008053	27829152	9.95	3,7,2,1,4,5,8,6
7	4	8924	36558317	10527	44073697	7515380	18	Hapmap24419-BTA-162106	36558317	9.86	6,2,3,4,5,9,8
8	4	13365	55763368	15735	65519029	9755661	38	BovineHD0400016706	61125903	10.7	6,9,2,1,3,5,8
9	4	23730	97674762	24213	99540028	1865266	5	BovineHD0400027868	99540028	9.3	4,3
10	5	16168	67417898	17489	72243381	4825483	3	ARS-BFGL-NGS-70198	72243381	9.29	6,9
11	5	20435	84539347	27159	109948232	2540888	60	BovineHD0500024659	86998734	12.96	1,5,3,2,4
12	6	4475	18036724	7462	29334848	11298124	106	BovineHD0600006497	23549700	11.07	3,4,5,2,6,7,9
13	6	13573	51683927	13598	51755112	71185	4	BovineHD0600014264	51731374	7.43	6
14	6	18708	71082832	26792	10275784	3167500	1019	BovineHD06000243	88919352	28.44	1,5,4,3,2,6,9,

Figure 17

32	12	11277	44331491	11285	44349649	18158	8	BovineHD12000122 84	44331491	7.59	4
33	12	15918	62561736	17398	68494212	5932476	30	BovineHD12000172 77	63068164	10.21	4,3,5
34	13	11798	53471793	15089	70173150	16701357	270	BovineHD13000170 74	59588546	14.97	4,5,3,1,2,8,7, 9
35	14	3505	13282075	5041	20691077	7409002	19	BovineHD14000059 26	20662703	8.65	6,8,3
36	14	9864	43961811	15451	69623868	25662057	49	BovineHD14000146 43	51548605	9.80	5,3,2,9,6,4,1, 7,8
37	15	2329	9897946	2334	9915788	17842	4	BovineHD15000026 10	9897946	7.50	8,7
38	15	6316	26178933	8176	33293128	7114195	21	BovineHD15000083 66	31105101	9.82	7,8,9,4,6,5
39	15	9855	39284002	13327	52111223	12827221	42	BovineHD15000122 01	43914509	10.93	8,7,9,1,5,2,4, 3,6
40	15	17079	66540919	17084	66551171	10252	3	BovineHD15000191 16	66543720	7.40	2,3
41	16	1694	8171169	2172	10545502	2374333	26	BovineHD16000023 26	8171169	7.50	1
42	16	3534	15737429	3596	16009799	272370	5	BovineHD16000042 72	15784091	10.47	3,4,7,6,5,2,9, 8
43	16	5299	21799660	16175	64955150	43155490	832	BovineHD16000146 22	52924145	16.47	1,5,2,4,3,6,7, 9,8
44	17	512	2467836	3752	13800376	11332540	12	BovineHD17000026 74	9472006	8.11	1
45	17	16389	61406860	16431	61535420	128560	9	ARS-BFGL-NGS- 26121	61522805	8.29	4
46	18	6383	21603442	6944	23535823	1932381	4	BovineHD18000066 66	21606994	8.23	4,5
47	18	11892	41653211	13902	48570545	6917334	51	BovineHD18000132 34	44778431	11.13	1,5,2,4
48	19	2020	8230088	3676	14585690	6355602	18	BovineHD19000038 60	14578566	8.34	1,2,6

Figure 17

49	19	7734	27998517	8035	29383514	1384997	9	BovineHD1900008608	29320178	8.70	1
50	19	9209	33351947	12120	46467474	13115527	105	BovineHD1900012270	43098630	11.33	1,5,6,3,4,2
51	19	12750	49013784	16762	62339802	13326018	60	BovineHD1900015719	55615219	11.38	7,8,6,9,1,3,4,5
52	20	5111	18072225	5122	18110885	38660	2	BovineHD2000005443	18110885	8.16	5,4,2
53	20	7852	28291423	14407	55744850	27453427	685	BovineHD2000010279	35981673	18.40	5,2,3,4,1,9,7,8,6
54	20	14681	56557595	19739	71359405	14801810	202	BovineHD2000019538	67376802	11.37	6,9,7,8,5,1,4,2,3
55	21	11020	43772475	11021	43773986	1511	2	BovineHD2100012534	43772475	7.84	9,7,6
56	22	6727	24494154	8368	31397754	6903600	37	Hapmap38325-BTA-53915	25113789	10.27	4,5,3,1,2
57	23	1077	4758944	3549	14524909	9765965	37	BovineHD2300002833	11512182	9.24	8,6,7,9,1,5,2,4,3
58	23	4429	18006108	7776	28819118	10813010	30	BovineHD2300007202	26369699	9.32	1,6,9,7,8
59	23	9221	33362170	9673	35604326	2242156	4	BovineHD2300010058	34251317	8.81	1,7
60	23	11058	41491498	13747	51051152	9559654	88	BovineHD2300012843	44312928	11.83	7,8,9,6,2,5,3,4,1
61	25	3879	12927936	3879	12927936	0	1	BovineHD2500003616	12927936	7.28	1

Figure 18, ctd.

A. Chr-5.1 MAS11




Figure 18, ctd.

B. Chr-5.2 MAS12




Figure 18, ctd.

C. Chr-5.3 MAS2




Figure 18, ctd.

D. Chr-5.4 MAS3




Figure 18, ctd.

E. Chr-5.5 MAS-INDEX




Figure 18, ctd.

F. Chr-5.6 SCS1




Figure 18, ctd.

G. Chr-5.7 SCS2




Figure 18, ctd.

H. Chr-5.8 SCS3




Figure 18, ctd.

I. Chr-5.9 SCS-INDEX




Figure 19, ctd.

A. Chr-6.1 MAS11




Figure 19, ctd.

B. Chr-6.2 MAS12





Figure 19, ctd.

C. Chr-6.3 MAS2



D. Chr-6.4 MAS3

Figure 19, ctd.




Figure 19, ctd.

E. Chr-6.5 MAS-INDEX




Figure 19, ctd.

F. Chr-6.6 SCS1




Figure 19, ctd.

G. Chr-6.7 SCS2




Figure 19, ctd.

H. Chr-6.8 SCS3




Figure 19, ctd.

I. Chr-6.9 SCS-INDEX




Figure 20, ctd
A. Chr-13.1 MAS11




Figure 20, ctd
B. Chr-13.2 MAS12




Figure 20, ctd
C. Chr-13.3 MAS2




Figure 20, ctd

D. Chr-13.4 MAS3




Figure 20, ctd
E. Chr-13.5 MAS-INDEX




Figure 20, ctd
F. Chr-13.6 SCS1




Figure 20, ctd
G. Chr-13.7 SCS2




Figure 20, ctd

H. Chr-13.8 SCS3




Figure 20, ctd
I. Chr-13.9 SCS-INDEX




Figure 21, ctd.
A. Chr-16.1 MAS11




Figure 21, ctd.

B. Chr-16.2 MAS12




Figure 21, ctd.

C. Chr-16.3 MAS2






Figure 21, ctd.

D. Chr-16.4 MAS3



E. Chr-16.5 MAS-INDEX

Figure 21, ctd.






Figure 21, ctd.

F. Chr-16.6 SCS1

Figure 21, ctd.

G. Chr-16.7 SCS2




Figure 21, ctd.

H. Chr-16.8 SCS3




Figure 21, ctd.
I. Chr-16.9 SCS-INDEX




Figure 22, ctd.
A. Chr-19.1 MAS11




Figure 22, ctd.
B. Chr-19.2 MAS12




Figure 22, ctd.

C. Chr-19.3 MAS2




Figure 22, ctd.

D. Chr-19.4 MAS3




Figure 22, ctd.
E. Chr-19.5 MAS-INDEX




Figure 22, ctd.
F. Chr-19.6 SCS1




Figure 22, ctd.

G. Chr-19.7 SCS2




Figure 22, ctd.

H. Chr-19.8 SCS3




Figure 22, ctd.
I. Chr-19.9 SCS-INDEX




Figure 23, ctd.
A. Chr-20.1 MAS11




Figure 23, ctd.
B. Chr-20.2 MAS12




Figure 23, ctd.

C. Chr-20.3 MAS2





Figure 23, ctd.

D. Chr-20.4 MAS3



E. Chr-20.5 MAS-INDEX

Figure 23, ctd.




Figure 23, ctd.
F. Chr-20.6 SCS1




Figure 23, ctd.

G. Chr-20.7 SCS2




Figure 23, ctd.

H. Chr-20.8 SCS3




Figure 23, ctd.
I. Chr-20.9 SCS-INDEX




Figure 24




Figure 1

